creatine has been researched along with Disease Models, Animal in 264 studies
Disease Models, Animal: Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The supplementation of creatine has shown a marked neuroprotective effect in mouse models of neurodegenerative diseases (Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis)." | 8.87 | Creatine in mouse models of neurodegeneration and aging. ( Bender, A; Elstner, M; Klopstock, T, 2011) |
| "Using a model of birth asphyxia, we previously reported significant structural and functional deficits in the diaphragm muscle in spiny mice, deficits that are prevented by supplementing the maternal diet with 5% creatine from mid-pregnancy." | 7.83 | Maternal Creatine Supplementation during Pregnancy Prevents Long-Term Changes in Diaphragm Muscle Structure and Function after Birth Asphyxia. ( Dickinson, H; Ellery, SJ; LaRosa, DA; Parkington, HC; Snow, RJ; Walker, DW, 2016) |
| "Mutations in the creatine (Cr) transporter (CrT) gene lead to cerebral creatine deficiency syndrome-1 (CCDS1), an X-linked metabolic disorder characterized by cerebral Cr deficiency causing intellectual disability, seizures, movement and autistic-like behavioural disturbances, language and speech impairment." | 7.83 | A mouse model for creatine transporter deficiency reveals early onset cognitive impairment and neuropathology associated with brain aging. ( Alessandrì, MG; Baroncelli, L; Cacciante, F; Cioni, G; Leuzzi, V; Molinaro, A; Napoli, D; Pizzorusso, T; Putignano, E; Tola, J, 2016) |
| "Pregnant spiny mice were fed a control or creatine-supplemented diet from mid-pregnancy, and 1 d before term (39 d), fetuses were delivered by c-section with or without 7." | 7.83 | Maternal creatine supplementation during pregnancy prevents acute and long-term deficits in skeletal muscle after birth asphyxia: a study of structure and function of hind limb muscle in the spiny mouse. ( Dickinson, H; Ellery, SJ; LaRosa, DA; Snow, RJ; Walker, DW, 2016) |
| "This study aimed to explore the effect and mechanisms of rhein on sepsis-induced acute kidney injury by injecting lipopolysaccharide (LPS) and cecal ligation and puncture (CLP) in vivo, and on LPS-induced HK-2 cells in vitro." | 7.81 | Rhein prevents endotoxin-induced acute kidney injury by inhibiting NF-κB activities. ( Fan, HY; Li, P; Qi, D; Sun, JF; Yu, C, 2015) |
| " We, therefore, utilized these methods to assess changes in glucose metabolism and metabolites in the rat lithium-pilocarpine model of epilepsy as markers of epileptogenesis from baseline to chronic spontaneous recurrent seizures (SRS)." | 7.78 | Changes in glucose metabolism and metabolites during the epileptogenic process in the lithium-pilocarpine model of epilepsy. ( Chung, JH; Im, KC; Kang, JK; Kim, JS; Kim, KS; Kim, ST; Kim, YI; Lee, EM; Park, GY; Shon, YM; Woo, CW, 2012) |
| "Increasing energy storage capacity by elevating creatine and phosphocreatine (PCr) levels to increase ATP availability is an attractive concept for protecting against ischaemia and heart failure." | 7.78 | Moderate elevation of intracellular creatine by targeting the creatine transporter protects mice from acute myocardial infarction. ( Aksentijevic, D; Bohl, S; Clarke, K; Faller, KM; Lygate, CA; Medway, DJ; Neubauer, S; Ostrowski, PJ; Schneider, JE; Sebag-Montefiore, L; ten Hove, M; Wallis, J; Watkins, H; Zervou, S, 2012) |
| "In order to confirm the roles of creatine (Cr) in epilepsy, we investigated the anti-convulsive effects of Cr, creatine transporter (CRT) and creatine kinases (CKs) against chemical-induced acute seizure activity and chronic epileptic seizure activity." | 7.76 | Effects of creatine and β-guanidinopropionic acid and alterations in creatine transporter and creatine kinases expression in acute seizure and chronic epilepsy models. ( Choi, SY; Kang, TC; Kim, DW; Kim, JE; Kwon, OS; Ryu, HJ; Song, HK; Yeo, SI, 2010) |
| "Creatine has a neuroprotective effect in mutant superoxide dismutase (G93A) transgenic mice, an animal model of motor neuron disease (MND)." | 7.70 | Oral administration of creatine monohydrate retards progression of motor neuron disease in the wobbler mouse. ( Ikeda, K; Iwasaki, Y; Kinoshita, M, 2000) |
| "The hydroxyl radical scavengers dimethylthiourea (DMTU), sodium benzoate, and dimethylsulfoxide (DMSO) were administered to rats before doxorubicin hydrochloride (ADR) (5 mg/kg, IV) to probe the role of free radicals in mediating proteinuria in doxorubicin hydrochloride nephrosis (AN)." | 7.68 | Amelioration of glomerular injury in doxorubicin hydrochloride nephrosis by dimethylthiourea. ( Houser, MT; Milner, LS; Wei, SH, 1991) |
| " Severe hyponatremia and hypoosmolality induced profound decreases in levels of brain electrolytes, amino acids (especially taurine), and creatine." | 7.67 | Adaptive decreases in amino acids (taurine in particular), creatine, and electrolytes prevent cerebral edema in chronically hyponatremic mice: rapid correction (experimental model of central pontine myelinolysis) causes dehydration and shrinkage of brain. ( Hauhart, RE; Nelson, JS; Thurston, JH, 1987) |
| "Epilepsy is one of the main symptoms in GAMT and CT1 deficiency, whereas the occurrence of febrile convulsions in infancy is a relatively common presenting symptom in all the three above-mentioned diseases." | 6.49 | Inborn errors of creatine metabolism and epilepsy. ( Battini, R; Cioni, G; Leuzzi, V; Mastrangelo, M, 2013) |
| " These trials have also posed unanswered questions about the optimal dosage of creatine and its beneficial effects on muscle fatigue, a measure distinct from muscle strength." | 6.42 | The role of creatine in the management of amyotrophic lateral sclerosis and other neurodegenerative disorders. ( Ellis, AC; Rosenfeld, J, 2004) |
| "Epilepsy is often considered to be a progressive neurological disease, and the nature of this progression remains unclear." | 5.72 | Insights into the development of pentylenetetrazole-induced epileptic seizures from dynamic metabolomic changes. ( Cheng, P; Jia, P; Liao, S; Meng, K; Xiao, C; Xu, R; Zhao, X; Zheng, X, 2022) |
| "Creatine was provided in drinking water for a total of 21 days." | 5.56 | Creatine supplementation in Walker-256 tumor-bearing rats prevents skeletal muscle atrophy by attenuating systemic inflammation and protein degradation signaling. ( Borges, FH; Cecchini, R; Cella, PS; Chimin, P; Deminice, R; Duarte, JA; Guarnier, FA; Guirro, PB; Marinello, PC; Ribeiro, DF; Testa, MTJ, 2020) |
| "Creatine (Cr) is a substrate for adenosine triphosphate synthesis, and it is the most used dietary supplement among professional and recreative athletes and sportsmen." | 5.51 | Creatine supplementation impairs airway inflammation in an experimental model of asthma involving P2 × 7 receptor. ( Almeida, FM; Andrade-Souza, AS; Aquino-Junior, JCJ; Bachi, ALL; Coutinho-Silva, R; Ferreira, SC; Garcia, M; Idzko, M; Müller, T; Oliveira, APL; Oliveira-Junior, MC; Rigonato-Oliveira, NC; Santos-Dias, A; Savio, LEB; Siepmann, T; Vieira, RP, 2019) |
| "Early diagnosis of hepatocellular carcinoma (HCC) remains challenging to date." | 5.42 | Metabolomics Identifies Biomarker Pattern for Early Diagnosis of Hepatocellular Carcinoma: from Diethylnitrosamine Treated Rats to Patients. ( Hu, C; Huang, X; Lin, X; Niu, J; Tan, Y; Wang, H; Wang, X; Yin, P; Zeng, J; Zhou, L, 2015) |
| "Treatment with creatine supplements ameliorated the hearing impairment of HD mice, suggesting that the impaired PCr-CK system in the cochlea of HD mice may contribute to their hearing impairment." | 5.37 | Dysregulated brain creatine kinase is associated with hearing impairment in mouse models of Huntington disease. ( Chen, CM; Chen, HM; Cheng, ML; Chern, Y; Lin, YJ; Lin, YS; Poon, PW; Soong, BW; Wang, CH; Wu, DR; Wu, YR; Yeh, WY, 2011) |
| "Creatine deposits were found in all TgCRND8 mice; the extent of deposition increased with age." | 5.36 | Association among amyloid plaque, lipid, and creatine in hippocampus of TgCRND8 mouse model for Alzheimer disease. ( Agrawal, V; Del Bigio, MR; Gallant, M; Gough, KM; Julian, R; Kastyak, M; Kuzyk, A; Rak, M; Sivakumar, G; Westaway, D, 2010) |
| "Myocardial infarction was induced in a subgroup of animals (BGP n = 15, control n = 15) by ligation of the left coronary artery resulting in a large ( approximately 50%) anterolateral MI and acute HF." | 5.34 | In vivo effects of myocardial creatine depletion on left ventricular function, morphology, and energy metabolism--consequences in acute myocardial infarction. ( Bollano, E; Lorentzon, M; Omerovic, E; Råmunddal, T; Soussi, B; Waagstein, F, 2007) |
| " We decided to administer it by intracerebroventricular infusion, to maximize its bioavailability to the brain." | 5.33 | Intracerebroventricular administration of creatine protects against damage by global cerebral ischemia in rat. ( Balestrino, M; Gandolfo, C; Izvarina, N; Korzhevskii, DE; Kostkin, VB; Lensman, M; Mourovets, VO; Otellin, VA; Perasso, L; Polenov, SA, 2006) |
| "Proteinuria was significantly lower in L-arginine-treated animals from week 24 onward (p<0." | 5.32 | Long-term dietary L-arginine supplementation attenuates proteinuria and focal glomerulosclerosis in experimental chronic renal transplant failure. ( Albrecht, EW; Smit-van Oosten, A; Stegeman, CA; van Goor, H, 2003) |
| "Creatine's effects were primarily lusitropic by delaying the onset of myocardial relaxation in all hearts." | 5.31 | Effect of creatine monohydrate on cardiac function in a rat model of endotoxemia. ( Hill, RC; Karne, NH; Vona-Davis, L; Wearden, PD, 2002) |
| "The supplementation of creatine has shown a marked neuroprotective effect in mouse models of neurodegenerative diseases (Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis)." | 4.87 | Creatine in mouse models of neurodegeneration and aging. ( Bender, A; Elstner, M; Klopstock, T, 2011) |
| " In patients, such myopathy is characterized by the gradual onset of proximal limb muscle weakness and a sudden increase in creatine excretion in 24h urine." | 4.80 | [The effect of corticotherapy on respiratory muscles]. ( Decramer, M; Gayan-Ramirez, G, 1998) |
| "We investigated the antidepressant effect of creatine (CRE) and taurine (TAU) mixtures on behavioural changes and biomarkers in stress-induced depression in Drosophila melanogaster and a mouse model." | 3.96 | Creatine and taurine mixtures alleviate depressive-like behaviour in Drosophila melanogaster and mice via regulating Akt and ERK/BDNF pathways. ( Hong, KB; Jo, K; Kim, S; Suh, HJ, 2020) |
| "Creatine Transporter Deficiency (CTD) is an inborn error of metabolism presenting with intellectual disability, behavioral disturbances and epilepsy." | 3.96 | Cyclocreatine treatment ameliorates the cognitive, autistic and epileptic phenotype in a mouse model of Creatine Transporter Deficiency. ( Alessandrì, MG; Baroncelli, L; Battini, R; Butt, M; Cacciante, F; Cerri, E; Cioni, G; Do, MT; Gennaro, M; Lupori, L; Mazziotti, R; McKew, JC; Pizzorusso, T; Putignano, E; Sagona, G, 2020) |
| "The objective of this study was to evaluate creatine as an anti-nociceptive compound in an animal model of thermal and inflammatory pain." | 3.88 | Effects of creatine supplementation on nociception in young male and female mice. ( Gonzales, EB; Izurieta Munoz, H; Sumien, N, 2018) |
| "This study aims to explore the effects of the exogenous hydrogen sulfide (H2S)-mediated scavenger receptor A (SR-A) signaling pathway on renal ischemia/reperfusion injury (IRI) by regulating endoplasmic reticulum (ER) stress-induced autophagy in rats." | 3.85 | Roles of the Exogenous H2S-Mediated SR-A Signaling Pathway in Renal Ischemia/ Reperfusion Injury in Regulating Endoplasmic Reticulum Stress-Induced Autophagy in a Rat Model. ( Ling, Q; Liu, JH; Wang, SG; Wang, T; Ye, ZQ; Yu, X, 2017) |
| "Ketamine has emerged as a novel strategy to treat refractory depression, producing rapid remission, but elicits some side effects that limit its use." | 3.83 | Creatine, Similar to Ketamine, Counteracts Depressive-Like Behavior Induced by Corticosterone via PI3K/Akt/mTOR Pathway. ( Colla, AR; Cunha, MP; Lieberknecht, V; Oliveira, Á; Pazini, FL; Rodrigues, AL; Rosa, JM, 2016) |
| "Using a model of birth asphyxia, we previously reported significant structural and functional deficits in the diaphragm muscle in spiny mice, deficits that are prevented by supplementing the maternal diet with 5% creatine from mid-pregnancy." | 3.83 | Maternal Creatine Supplementation during Pregnancy Prevents Long-Term Changes in Diaphragm Muscle Structure and Function after Birth Asphyxia. ( Dickinson, H; Ellery, SJ; LaRosa, DA; Parkington, HC; Snow, RJ; Walker, DW, 2016) |
| "Mutations in the creatine (Cr) transporter (CrT) gene lead to cerebral creatine deficiency syndrome-1 (CCDS1), an X-linked metabolic disorder characterized by cerebral Cr deficiency causing intellectual disability, seizures, movement and autistic-like behavioural disturbances, language and speech impairment." | 3.83 | A mouse model for creatine transporter deficiency reveals early onset cognitive impairment and neuropathology associated with brain aging. ( Alessandrì, MG; Baroncelli, L; Cacciante, F; Cioni, G; Leuzzi, V; Molinaro, A; Napoli, D; Pizzorusso, T; Putignano, E; Tola, J, 2016) |
| "Pregnant spiny mice were fed a control or creatine-supplemented diet from mid-pregnancy, and 1 d before term (39 d), fetuses were delivered by c-section with or without 7." | 3.83 | Maternal creatine supplementation during pregnancy prevents acute and long-term deficits in skeletal muscle after birth asphyxia: a study of structure and function of hind limb muscle in the spiny mouse. ( Dickinson, H; Ellery, SJ; LaRosa, DA; Snow, RJ; Walker, DW, 2016) |
| "This study aimed to explore the effect and mechanisms of rhein on sepsis-induced acute kidney injury by injecting lipopolysaccharide (LPS) and cecal ligation and puncture (CLP) in vivo, and on LPS-induced HK-2 cells in vitro." | 3.81 | Rhein prevents endotoxin-induced acute kidney injury by inhibiting NF-κB activities. ( Fan, HY; Li, P; Qi, D; Sun, JF; Yu, C, 2015) |
| " The present paper is the continuation of our previous study which has shown an increased occurrence of creatine inclusions in rat hippocampal formations from the acute phase of pilocarpine-induced status epilepticus (SE) and positive correlation between their quantity and the total time of seizure activity within the observation period." | 3.79 | Differences in the hippocampal frequency of creatine inclusions between the acute and latent phases of pilocarpine model defined using synchrotron radiation-based FTIR microspectroscopy. ( Chwiej, J; Dumas, P; Janeczko, K; Kutorasinska, J; Sandt, C; Setkowicz, Z, 2013) |
| " We, therefore, utilized these methods to assess changes in glucose metabolism and metabolites in the rat lithium-pilocarpine model of epilepsy as markers of epileptogenesis from baseline to chronic spontaneous recurrent seizures (SRS)." | 3.78 | Changes in glucose metabolism and metabolites during the epileptogenic process in the lithium-pilocarpine model of epilepsy. ( Chung, JH; Im, KC; Kang, JK; Kim, JS; Kim, KS; Kim, ST; Kim, YI; Lee, EM; Park, GY; Shon, YM; Woo, CW, 2012) |
| "The potential role of metabolic impairments in the pathophysiology of depression is motivating researchers to evaluate the treatment efficacy of creatine, a naturally occurring energetic and neuroprotective compound found in brain and muscle tissues." | 3.78 | Sex-specific antidepressant effects of dietary creatine with and without sub-acute fluoxetine in rats. ( Allen, PJ; D'Anci, KE; Kanarek, RB; Renshaw, PF, 2012) |
| "Increasing energy storage capacity by elevating creatine and phosphocreatine (PCr) levels to increase ATP availability is an attractive concept for protecting against ischaemia and heart failure." | 3.78 | Moderate elevation of intracellular creatine by targeting the creatine transporter protects mice from acute myocardial infarction. ( Aksentijevic, D; Bohl, S; Clarke, K; Faller, KM; Lygate, CA; Medway, DJ; Neubauer, S; Ostrowski, PJ; Schneider, JE; Sebag-Montefiore, L; ten Hove, M; Wallis, J; Watkins, H; Zervou, S, 2012) |
| " Acetaminophen is a commonly used analgesic and antipyretic agent which, at high doses, causes liver and kidney necrosis in man and animals." | 3.77 | Evaluation of phytoconstituents and anti-nephrotoxic and antioxidant activities of Monochoria vaginalis. ( Kumar, BS; Kumar, RP; Palani, S; Raja, S; Selvaraj, R, 2011) |
| "In order to confirm the roles of creatine (Cr) in epilepsy, we investigated the anti-convulsive effects of Cr, creatine transporter (CRT) and creatine kinases (CKs) against chemical-induced acute seizure activity and chronic epileptic seizure activity." | 3.76 | Effects of creatine and β-guanidinopropionic acid and alterations in creatine transporter and creatine kinases expression in acute seizure and chronic epilepsy models. ( Choi, SY; Kang, TC; Kim, DW; Kim, JE; Kwon, OS; Ryu, HJ; Song, HK; Yeo, SI, 2010) |
| "Glutaric acidemia type I (GA-I) is an inherited metabolic disease characterized by striatal degeneration, seizures, and accumulation of glutaric acid (GA)." | 3.74 | Creatine decreases convulsions and neurochemical alterations induced by glutaric acid in rats. ( Ferreira, J; Fighera, MR; Fiorenza, NG; Furian, AF; Magni, DV; Mello, CF; Oliveira, MS; Royes, LF, 2007) |
| "The known neuroprotective effects of minocycline and creatine in animal models of amyotrophic lateral sclerosis (ALS) led us to examine whether the combination of these agents would result in increased neuroprotection." | 3.72 | Additive neuroprotective effects of minocycline with creatine in a mouse model of ALS. ( Friedlander, RM; Narayanan, M; Zhang, W, 2003) |
| "This study investigated the effects of riluzole (Ril), creatine (Cr) and a combination of these treatments on the onset and progression of clinical signs and neuropathology in an animal model of familial amyotrophic lateral sclerosis, the G93A transgenic mouse (n=13-17 per group)." | 3.72 | Creatine supplementation and riluzole treatment provide similar beneficial effects in copper, zinc superoxide dismutase (G93A) transgenic mice. ( da Silva, S; Jiang, F; Snow, RJ; Tarnopolsky, MA; Turnbull, J, 2003) |
| "Creatine has a neuroprotective effect in mutant superoxide dismutase (G93A) transgenic mice, an animal model of motor neuron disease (MND)." | 3.70 | Oral administration of creatine monohydrate retards progression of motor neuron disease in the wobbler mouse. ( Ikeda, K; Iwasaki, Y; Kinoshita, M, 2000) |
| "The hydroxyl radical scavengers dimethylthiourea (DMTU), sodium benzoate, and dimethylsulfoxide (DMSO) were administered to rats before doxorubicin hydrochloride (ADR) (5 mg/kg, IV) to probe the role of free radicals in mediating proteinuria in doxorubicin hydrochloride nephrosis (AN)." | 3.68 | Amelioration of glomerular injury in doxorubicin hydrochloride nephrosis by dimethylthiourea. ( Houser, MT; Milner, LS; Wei, SH, 1991) |
| " Severe hyponatremia and hypoosmolality induced profound decreases in levels of brain electrolytes, amino acids (especially taurine), and creatine." | 3.67 | Adaptive decreases in amino acids (taurine in particular), creatine, and electrolytes prevent cerebral edema in chronically hyponatremic mice: rapid correction (experimental model of central pontine myelinolysis) causes dehydration and shrinkage of brain. ( Hauhart, RE; Nelson, JS; Thurston, JH, 1987) |
| "Creatine is a key player in heart contraction and energy metabolism." | 2.72 | Role of Creatine in the Heart: Health and Disease. ( Balestrino, M, 2021) |
| "Creatine is a principle component of the creatine kinase (CK) phosphagen system common to all vertebrates." | 2.53 | Augmentation of Creatine in the Heart. ( Lygate, CA; Russell, AJ; Whittington, HJ; Zervou, S, 2016) |
| "Creatine (Cr) is a natural compound that plays an important role in cellular energy homeostasis." | 2.53 | Creatine for neuroprotection in neurodegenerative disease: end of story? ( Bender, A; Klopstock, T, 2016) |
| "Epilepsy is one of the main symptoms in GAMT and CT1 deficiency, whereas the occurrence of febrile convulsions in infancy is a relatively common presenting symptom in all the three above-mentioned diseases." | 2.49 | Inborn errors of creatine metabolism and epilepsy. ( Battini, R; Cioni, G; Leuzzi, V; Mastrangelo, M, 2013) |
| "Studies using the mdx model of Duchenne muscular dystrophy have found evidence of enhanced mitochondrial function, reduced intra-cellular calcium and improved performance with CrM supplementation." | 2.44 | Clinical use of creatine in neuromuscular and neurometabolic disorders. ( Tarnopolsky, MA, 2007) |
| "Creatine is a critical component in maintaining cellular energy homeostasis, and its administration has been reported to be neuroprotective in a wide number of both acute and chronic experimental models of neurological disease." | 2.44 | The neuroprotective role of creatine. ( Ferrante, RJ; Klein, AM, 2007) |
| "The pathogenesis of Parkinson's disease (PD) remains obscure, but there is increasing evidence that impairment of mitochondrial function, oxidative damage, and inflammation are contributing factors." | 2.42 | Mitochondria, oxidative damage, and inflammation in Parkinson's disease. ( Beal, MF, 2003) |
| "A wide variety of models of Huntington's disease have been developed including yeast, Caenorhabditis elegans, Drosophila melanogaster and mouse." | 2.42 | Experimental therapeutics in Huntington's disease: are models useful for therapeutic trials? ( Bates, GP; Hockly, E, 2003) |
| " These trials have also posed unanswered questions about the optimal dosage of creatine and its beneficial effects on muscle fatigue, a measure distinct from muscle strength." | 2.42 | The role of creatine in the management of amyotrophic lateral sclerosis and other neurodegenerative disorders. ( Ellis, AC; Rosenfeld, J, 2004) |
| " MMF was designed to enhance the oral bioavailability of the parent compound." | 2.40 | Mizoribine and mycophenolate mofetil. ( Ishikawa, H, 1999) |
| "Creatine is a dietary supplement with potential capacity to stimulate the phosphocreatine pathway and protein synthesis, through the stimulation of the PI3-K/AKT and mTOR cascade, its use in populations with reduced muscle preservation capacity (such as the older adults) can be an interesting and low-cost alternative." | 1.72 | Renal, hepatic and muscle effects of creatine supplementation in an older adults experimental model. ( Alves Leandro, JV; Banov, GC; Caldeira, EJ; Delforno, MC; Gonçalves Teixeira, KF; Iatecola, A; Inácio Cardozo, MF; Ramos Fernandes, VA; Rodrigues da Cunha, M; Shmayev, M, 2022) |
| "Creatine treatment was associated with enhanced cellular basal respiration in vitro and increased tumor cell proliferation in vivo." | 1.72 | Cyclocreatine Suppresses Creatine Metabolism and Impairs Prostate Cancer Progression. ( Fleming, J; Ford, CA; Leung, HY; Lynch, V; Mackay, G; Mui, E; Patel, R; Rodgers, L; Rushworth, LK; Sansom, OJ; Sumpton, D; Vande Voorde, J; Watson, D; Zhang, T, 2022) |
| "Epilepsy is often considered to be a progressive neurological disease, and the nature of this progression remains unclear." | 1.72 | Insights into the development of pentylenetetrazole-induced epileptic seizures from dynamic metabolomic changes. ( Cheng, P; Jia, P; Liao, S; Meng, K; Xiao, C; Xu, R; Zhao, X; Zheng, X, 2022) |
| "Curcumin (CUR) has been reported to provide neuroprotective effects on neurological disorders and modulate the gut flora in intestinal-related diseases." | 1.72 | Curcumin-driven reprogramming of the gut microbiota and metabolome ameliorates motor deficits and neuroinflammation in a mouse model of Parkinson's disease. ( Cui, C; Han, Y; Li, G; Li, H; Yu, H; Zhang, B, 2022) |
| "Disease progression was investigated at 4 time points, from 9 to 18 months of age, and in 4 regions: cortex, hippocampus, striatum, and thalamus." | 1.72 | Spatio-temporal metabolic rewiring in the brain of TgF344-AD rat model of Alzheimer's disease. ( López-Gil, X; Muñoz-Moreno, E; Simões, RV; Soria, G; Tudela, R, 2022) |
| "Creatine is an organic compound used as fast phosphate energy buffer to recycle ATP, important in tissues with high energy demand such as muscle or brain." | 1.62 | A new rat model of creatine transporter deficiency reveals behavioral disorder and altered brain metabolism. ( Binz, PA; Braissant, O; Bruce, SJ; Cudalbu, C; Duran-Trio, L; Fernandes-Pires, G; Grosse, J; Roux-Petronelli, C; Sandi, C; Simicic, D, 2021) |
| "Detecting Alzheimer's disease (AD) at an early stage brings a lot of benefits including disease management and actions to slow the progression of the disease." | 1.62 | Early detection of Alzheimer's disease using creatine chemical exchange saturation transfer magnetic resonance imaging. ( Chen, L; Duan, W; Li, T; Lu, H; van Zijl, PCM; Wei, Z; Wong, PC; Xu, J, 2021) |
| " Exposure at the no observed adverse effect level in creatine transporter-deficient (554 μg*hr/ml) mice exceeded exposure at the maximum tolerated dose in wild-type (248 μg*hr/ml) mice." | 1.62 | Use of an animal model of disease for toxicology enables identification of a juvenile no observed adverse effect level for cyclocreatine in creatine transporter deficiency. ( Butt, M; Cavagnaro, J; Do, MT; McKew, JC; Terse, PS, 2021) |
| "Creatine was provided in drinking water for a total of 21 days." | 1.56 | Creatine supplementation in Walker-256 tumor-bearing rats prevents skeletal muscle atrophy by attenuating systemic inflammation and protein degradation signaling. ( Borges, FH; Cecchini, R; Cella, PS; Chimin, P; Deminice, R; Duarte, JA; Guarnier, FA; Guirro, PB; Marinello, PC; Ribeiro, DF; Testa, MTJ, 2020) |
| "Lipopolysaccharide (LPS)-induced encephalopathy induces neuroinflammation." | 1.51 | Anti-inflammatory agent, OKN-007, reverses long-term neuroinflammatory responses in a rat encephalopathy model as assessed by multi-parametric MRI: implications for aging-associated neuroinflammation. ( Gulej, R; Lawrence, B; McKenzie, T; Morton, KA; Saunders, D; Smith, N; Towner, RA, 2019) |
| "Creatine (Cr) is a substrate for adenosine triphosphate synthesis, and it is the most used dietary supplement among professional and recreative athletes and sportsmen." | 1.51 | Creatine supplementation impairs airway inflammation in an experimental model of asthma involving P2 × 7 receptor. ( Almeida, FM; Andrade-Souza, AS; Aquino-Junior, JCJ; Bachi, ALL; Coutinho-Silva, R; Ferreira, SC; Garcia, M; Idzko, M; Müller, T; Oliveira, APL; Oliveira-Junior, MC; Rigonato-Oliveira, NC; Santos-Dias, A; Savio, LEB; Siepmann, T; Vieira, RP, 2019) |
| "The sequence of events in hepatic encephalopathy (HE) remains unclear." | 1.51 | Longitudinal neurometabolic changes in the hippocampus of a rat model of chronic hepatic encephalopathy. ( Braissant, O; Cudalbu, C; Grosse, J; McLin, VA; Pierzchala, K; Rackayová, V, 2019) |
| "Creatine treatment also restored the expression of the mitochondrial mass marker Porin and reduced the expression of antioxidant enzymes Heme oxygenase 1 (HO1) and NAD(P)H Quinone Dehydrogenase 1 (NQO1), suggesting a beneficial effect at the level of mitochondria and oxidative stress." | 1.48 | Neuroprotective Effects of Creatine in the CMVMJD135 Mouse Model of Spinocerebellar Ataxia Type 3. ( Duarte-Silva, S; Maciel, P; Neves-Carvalho, A; Silva, JM; Silva-Fernandes, A; Soares-Cunha, C; Teixeira-Castro, A; Vieira, R, 2018) |
| "Creatine treatment increased PGC-1α, FNDC5 and BDNF mRNA in the hippocampus as well as BDNF immunocontent." | 1.48 | Subchronic administration of creatine produces antidepressant-like effect by modulating hippocampal signaling pathway mediated by FNDC5/BDNF/Akt in mice. ( Cunha, MP; Lieberknecht, V; Pazini, FL; Rodrigues, ALS, 2018) |
| "Acute renal injury caused by acute necrotizing pancreatitis (ANP) is a common complication that is associated with a high rate of mortality." | 1.43 | Paeoniflorin ameliorates acute necrotizing pancreatitis and pancreatitis‑induced acute renal injury. ( He, X; Li, C; Mei, F; Shi, Q; Wang, P; Wang, W; Zhao, L; Zuo, T, 2016) |
| " Although there was no difference in kainate dosing or seizure count between them, the metabolic pattern of injury was different." | 1.43 | Metabolic injury in a variable rat model of post-status epilepticus. ( de Lanerolle, N; Kelly, KM; Pan, JW; Pearce, PS; Rapuano, A; Wu, Y, 2016) |
| "Vascular calcification is a risk factor for causing cardiovascular events and has a high prevalence among chronic kidney disease (CKD) patients." | 1.42 | High phosphorus level leads to aortic calcification via β-catenin in chronic kidney disease. ( Fan, X; Feng, JM; Liu, LL; Ma, JF; Ren, C; Sun, L; Sun, W; Sun, YT; Wang, LN; Xu, TH; Yao, L, 2015) |
| "Brain edema was maximal on MR imaging 3 h after poisoning." | 1.42 | Early brain magnetic resonance imaging can predict short and long-term outcomes after organophosphate poisoning in a rat model. ( Cohen, Y; Eisenkraft, A; Kadar, T; Kassirer, M; Milk, N; Rosman, Y; Shiyovich, A; Shrot, S; Tauber, M, 2015) |
| "Early diagnosis of hepatocellular carcinoma (HCC) remains challenging to date." | 1.42 | Metabolomics Identifies Biomarker Pattern for Early Diagnosis of Hepatocellular Carcinoma: from Diethylnitrosamine Treated Rats to Patients. ( Hu, C; Huang, X; Lin, X; Niu, J; Tan, Y; Wang, H; Wang, X; Yin, P; Zeng, J; Zhou, L, 2015) |
| "Bioenergetic failure is a feature of Alzheimer's disease (AD)." | 1.40 | Reduced levels of mitochondrial complex I subunit NDUFB8 and linked complex I + III oxidoreductase activity in the TgCRND8 mouse model of Alzheimer's disease. ( Bazinet, RP; Francis, BM; Gupta, S; Maj, M; Mount, HT; Robinson, B; Song, BJ; Yang, J, 2014) |
| "The pharmacokinetic (PK) studies of phosphocreatine (PCr) and its active metabolite creatine (Cr) are considerably lacking." | 1.40 | Pharmacokinetics of phosphocreatine and its active metabolite creatine in the mouse plasma and myocardium. ( Han, GZ; Liu, KX; Lv, L; Sun, HJ; Wang, CY; Xu, L, 2014) |
| "Bilirubin treatment also decreased the amount of mesangial matrix, lowered the expression of renal collagen IV and transforming growth factor (TGF)-β1, and reduced the level of apoptosis in the kidney, compared to the DM group." | 1.40 | Effect of bilirubin on triglyceride synthesis in streptozotocin-induced diabetic nephropathy. ( Ahn, SY; Baek, SH; Chae, DW; Chin, HJ; Kim, S; Lee, ES; Na, KY; Xu, J, 2014) |
| "Myo-inositol (mIns) is a marker of glial cells proliferation and has been shown to increase in early Alzheimer's disease (AD) pathology." | 1.39 | MICEST: a potential tool for non-invasive detection of molecular changes in Alzheimer's disease. ( Cai, K; Crescenzi, R; Hariharan, H; Haris, M; Kogan, F; Nath, K; Reddy, R; Singh, A, 2013) |
| "Murine models of Alzheimer's disease (AD) provide means to detect and follow biomarker changes similar to those observed in humans." | 1.38 | Systematic evaluation of magnetic resonance imaging and spectroscopy techniques for imaging a transgenic model of Alzheimer's disease (AβPP/PS1). ( Alquézar, C; Antequera, D; Barrios, L; Bartolomé, F; Carro, E; Cerdán, S; Esteras, N; Martín-Requero, A, 2012) |
| "Creatine has been shown to play a significant role in health and disease." | 1.38 | Antidepressant-like effect of creatine in mice involves dopaminergic activation. ( Bettio, LE; Capra, JC; Cunha, MP; Jacinto, J; Machado, DG; Rodrigues, AL, 2012) |
| "Recently, the clinical spectrum of dominant optic atrophy has been extended to frequent syndromic forms, exhibiting various degrees of neurological and muscle impairments frequently found in mitochondrial diseases." | 1.38 | The human OPA1delTTAG mutation induces premature age-related systemic neurodegeneration in mouse. ( Angebault, C; Bielicki, G; Boddaert, N; Brabet, P; Cazevieille, C; Chaix, B; Delettre, C; Gueguen, N; Hamel, CP; Lenaers, G; Mausset-Bonnefont, AL; Puel, JL; Renou, JP; Reynier, P; Rigau, V; Sarzi, E; Seveno, M; Wang, J, 2012) |
| "Mice were tested for learning and memory deficits and assayed for Cr and neurotransmitter levels." | 1.37 | Creatine transporter (CrT; Slc6a8) knockout mice as a model of human CrT deficiency. ( Clark, JF; Degrauw, TJ; Graham, DL; Schaefer, TL; Skelton, MR; Vorhees, CV; Williams, MT, 2011) |
| "Treatment with creatine supplements ameliorated the hearing impairment of HD mice, suggesting that the impaired PCr-CK system in the cochlea of HD mice may contribute to their hearing impairment." | 1.37 | Dysregulated brain creatine kinase is associated with hearing impairment in mouse models of Huntington disease. ( Chen, CM; Chen, HM; Cheng, ML; Chern, Y; Lin, YJ; Lin, YS; Poon, PW; Soong, BW; Wang, CH; Wu, DR; Wu, YR; Yeh, WY, 2011) |
| "We utilized a global cerebral ischemia model induced by arresting the heart with a combination of hypovolemia and intracardiac injections of a cold potassium chloride solution in order to study the potential therapeutic benefits of human mesenchymal stem cells (hMSCs) on global cerebral ischemia." | 1.36 | Therapeutic benefits of human mesenchymal stem cells derived from bone marrow after global cerebral ischemia. ( Hamada, H; Harada, K; Honmou, O; Houkin, K; Kocsis, JD; Liu, H; Miyata, K; Suzuki, J; Zheng, W, 2010) |
| "The Tacrolimus-treated group developed a more aggressive tumor and a drug-related nephrotoxic effect." | 1.36 | Action of tacrolimus on Wistar rat kidneys implanted with Walker 256 carcinosarcoma. ( Czeczko, NG; Dietz, UA; Inácio, CM; Malafaia, O; Marcondes, CA; Nassif, PA; Ribas Filho, JM, 2010) |
| "To develop a reliable surgical model of acute hepatic failure and hyperammonemia in rats that avoids porto-systemic shunt and bile duct ligation, applicable to hepatic encephalopathy research." | 1.36 | A new experimental model for acute hepatic failure in rats. ( Bellodi-Privato, M; D'Albuquerque, LA; Kubrusly, MS; Leite, KR; Machado, MC; Molan, NT; Teixeira, AR, 2010) |
| "Creatine deposits were found in all TgCRND8 mice; the extent of deposition increased with age." | 1.36 | Association among amyloid plaque, lipid, and creatine in hippocampus of TgCRND8 mouse model for Alzheimer disease. ( Agrawal, V; Del Bigio, MR; Gallant, M; Gough, KM; Julian, R; Kastyak, M; Kuzyk, A; Rak, M; Sivakumar, G; Westaway, D, 2010) |
| "After nitroglycerin administration, the migraine rat model was established according to ethology evaluation." | 1.35 | Increased metabolite concentration in migraine rat model by proton MR spectroscopy in vivo and ex vivo. ( Gu, T; Li, CF; Ma, XX; Ma, Z; Wang, SJ, 2008) |
| "Cerebral fat embolism induced by a triolein emulsion resulted in no significant change in the major metabolites of the brain in the acute stage, except for an elevated lipid/Cr ratio, which suggests the absence of any significant hypoxic-ischemic changes in the lesions embolized using a fat emulsion." | 1.35 | Proton magnetic resonance spectroscopic findings of cerebral fat embolism induced by triolein emulsion in cats. ( Baik, SK; Chang, KH; Cho, BM; Choi, SH; Kim, DH; Kim, HJ; Kim, YW; Lee, JW; Lee, SH, 2008) |
| "Although hydrocephalus is usually considered a disorder of periventricular white matter, disturbance of gray matter is probably also involved." | 1.35 | Gray matter metabolism in acute and chronic hydrocephalus. ( Eyjolfsson, EM; Kondziella, D; Risa, O; Saether, O; Sonnewald, U, 2009) |
| "The effect of experimentally induced acute renal failure (ARF) on neuronal cell activation was investigated by immunohistochemistry for Fos and Fra-2 in the rat brain." | 1.35 | Neuronal activation in the CNS during different forms of acute renal failure in rats. ( Bahner, U; Boor, P; Gallatz, K; Heidland, A; Klassen, A; Palkovits, M; Sebekova, K, 2009) |
| "We used a mouse model of transient middle cerebral artery occlusion." | 1.35 | In vivo neuroprotection by a creatine-derived compound: phosphocreatine-Mg-complex acetate. ( Adriano, E; Balestrino, M; Burov, SV; Gandolfo, C; Perasso, L; Ruggeri, P, 2009) |
| " Exogenously administrated NAC might reduce toxic effects of Cd on the kidney without any reduction in tissue Cd level." | 1.35 | Influence of N-acetylcysteine on renal toxicity of cadmium in rats. ( Aktoz, T; Atakan, IH; Aydoğdu, N; Inci, O; Kaplan, M; Ozpuyan, F; Seren, G; Tokuç, B, 2008) |
| "Myocardial infarction was induced in a subgroup of animals (BGP n = 15, control n = 15) by ligation of the left coronary artery resulting in a large ( approximately 50%) anterolateral MI and acute HF." | 1.34 | In vivo effects of myocardial creatine depletion on left ventricular function, morphology, and energy metabolism--consequences in acute myocardial infarction. ( Bollano, E; Lorentzon, M; Omerovic, E; Råmunddal, T; Soussi, B; Waagstein, F, 2007) |
| "Prion diseases are fatal chronic neurodegenerative diseases." | 1.34 | MRI and MRS alterations in the preclinical phase of murine prion disease: association with neuropathological and behavioural changes. ( Anthony, DC; Blamire, AM; Broom, KA; Griffin, JL; Lowe, JP; Perry, VH; Scott, H; Sibson, NR; Styles, P, 2007) |
| " This study suggests that natriuresis observed only after higher centrally HoS stimuli with a rightward shift of dose-response curve provides evidence of a down-regulation of target organ responsiveness of periventricular areas of genetic hypertensive rats." | 1.33 | Altered renal sodium handling in spontaneously hypertensive rats (SHR) after hypertonic saline intracerebroventricular injection: role of renal nerves. ( Gontijo, JA; Guadagnini, D, 2006) |
| " We decided to administer it by intracerebroventricular infusion, to maximize its bioavailability to the brain." | 1.33 | Intracerebroventricular administration of creatine protects against damage by global cerebral ischemia in rat. ( Balestrino, M; Gandolfo, C; Izvarina, N; Korzhevskii, DE; Kostkin, VB; Lensman, M; Mourovets, VO; Otellin, VA; Perasso, L; Polenov, SA, 2006) |
| "Proteinuria was significantly lower in L-arginine-treated animals from week 24 onward (p<0." | 1.32 | Long-term dietary L-arginine supplementation attenuates proteinuria and focal glomerulosclerosis in experimental chronic renal transplant failure. ( Albrecht, EW; Smit-van Oosten, A; Stegeman, CA; van Goor, H, 2003) |
| "Pretreatment with pargyline attenuated the MPTP-induced clinical signs, MRI and MRS changes, and the histopathological and immunoreactivity alterations." | 1.32 | Proton magnetic resonance imaging and spectroscopy identify metabolic changes in the striatum in the MPTP feline model of parkinsonism. ( Hadjiconstantinou, M; Neff, NH; Podell, M; Smith, MA, 2003) |
| "Creatine treatment started at 6, 8, and 10 weeks of age, analogous to early, middle, and late stages of human HD, significantly extended survival at both the 6- and 8-week starting points." | 1.32 | Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice. ( Beal, MF; Dedeoglu, A; Ferrante, KL; Ferrante, RJ; Hersch, SM; Kubilus, JK; Yang, L, 2003) |
| "So far ASPA deficiency and elevated NAA have been ascribed with the CD." | 1.32 | Expression of glutamate transporter, GABRA6, serine proteinase inhibitor 2 and low levels of glutamate and GABA in the brain of knock-out mouse for Canavan disease. ( Campbell, GA; Ezell, EL; Matalon, R; Michals-Matalon, K; Quast, MJ; Rady, PL; Rassin, DK; Surendran, S; Szucs, S; Tyring, SK; Wei, J, 2003) |
| "Dunning rat prostate cancer cells were injected into the prostate by open surgery." | 1.32 | Dynamic magnetic resonance tomography and proton magnetic resonance spectroscopy of prostate cancers in rats treated by radiotherapy. ( Fink, C; Grobholz, R; Heilmann, M; Huber, PE; Kiessling, F; Krix, M; Lichy, MP; Meding, J; Peschke, P; Schlemmer, HP, 2004) |
| "Creatine (3 mM) was applied to tissue slices of the study groups 2 hours before the insult." | 1.32 | Creatine protects the immature brain from hypoxic-ischemic injury. ( Berger, R; Jensen, A; Middelanis, J; Mies, G; Vaihinger, HM; Wilken, B, 2004) |
| "Thus creatine treatment seems to reduce the spread of secondary injury." | 1.31 | Protective effects of oral creatine supplementation on spinal cord injury in rats. ( Fouad, K; Hausmann, ON; Schwab, ME; Wallimann, T, 2002) |
| "Glomerulonephritis was then induced in these mice." | 1.31 | Genetically modified bone marrow continuously supplies anti-inflammatory cells and suppresses renal injury in mouse Goodpasture syndrome. ( Eto, Y; Hisada, Y; Hosoya, T; Kawamura, T; Ohashi, T; Shen, JS; Utsunomiya, Y; Yokoo, T, 2001) |
| " Using this assay, we show that Congo red and chrysamine G can modulate aggregate formation, but show complex dose-response curves." | 1.31 | Inhibition of polyglutamine aggregation in R6/2 HD brain slices-complex dose-response profiles. ( Bates, GP; Hockly, E; Klunk, WE; Li, XJ; Mahal, A; Murray, KD; Portier, R; Smith, DL; Wanker, E; Woodman, B, 2001) |
| "Creatine's effects were primarily lusitropic by delaying the onset of myocardial relaxation in all hearts." | 1.31 | Effect of creatine monohydrate on cardiac function in a rat model of endotoxemia. ( Hill, RC; Karne, NH; Vona-Davis, L; Wearden, PD, 2002) |
| "The gene defect in Huntington's disease (HD) may result in an impairment of energy metabolism." | 1.30 | Neuroprotective effects of creatine and cyclocreatine in animal models of Huntington's disease. ( Beal, MF; Ferrante, RJ; Jenkins, BG; Kaddurah-Daouk, R; Matthews, RT; Rosen, BR; Yang, L, 1998) |
| "The effect of experimental acute renal failure on the intestinal permeability measured by differently sized polyethylene glycols (PEG) was studied in rats." | 1.28 | Reduced intestinal permeability measured by differently sized polyethylene glycols in acute uremic rats. ( Denneberg, T; Magnusson, KE; Magnusson, M; Sundqvist, T, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 8 (3.03) | 18.7374 |
| 1990's | 20 (7.58) | 18.2507 |
| 2000's | 87 (32.95) | 29.6817 |
| 2010's | 122 (46.21) | 24.3611 |
| 2020's | 27 (10.23) | 2.80 |
| Authors | Studies |
|---|---|
| Ramos Fernandes, VA | 1 |
| Delforno, MC | 1 |
| Banov, GC | 1 |
| Shmayev, M | 1 |
| Alves Leandro, JV | 1 |
| Gonçalves Teixeira, KF | 1 |
| Iatecola, A | 1 |
| Inácio Cardozo, MF | 1 |
| Caldeira, EJ | 1 |
| Rodrigues da Cunha, M | 1 |
| Patel, R | 1 |
| Ford, CA | 1 |
| Rodgers, L | 1 |
| Rushworth, LK | 1 |
| Fleming, J | 1 |
| Mui, E | 1 |
| Zhang, T | 1 |
| Watson, D | 1 |
| Lynch, V | 1 |
| Mackay, G | 1 |
| Sumpton, D | 1 |
| Sansom, OJ | 1 |
| Vande Voorde, J | 1 |
| Leung, HY | 1 |
| Zhao, X | 1 |
| Cheng, P | 1 |
| Xu, R | 1 |
| Meng, K | 1 |
| Liao, S | 1 |
| Jia, P | 1 |
| Zheng, X | 1 |
| Xiao, C | 1 |
| Cui, C | 1 |
| Han, Y | 1 |
| Li, H | 1 |
| Yu, H | 1 |
| Zhang, B | 2 |
| Li, G | 1 |
| Muñoz-Moreno, E | 1 |
| Simões, RV | 1 |
| Tudela, R | 1 |
| López-Gil, X | 1 |
| Soria, G | 1 |
| Bellissimo, CA | 1 |
| Delfinis, LJ | 1 |
| Hughes, MC | 1 |
| Turnbull, PC | 1 |
| Gandhi, S | 1 |
| DiBenedetto, SN | 1 |
| Rahman, FA | 1 |
| Tadi, P | 1 |
| Amaral, CA | 1 |
| Dehghani, A | 1 |
| Cobley, JN | 1 |
| Quadrilatero, J | 1 |
| Schlattner, U | 1 |
| Perry, CGR | 1 |
| Towner, RA | 1 |
| Saunders, D | 1 |
| Smith, N | 1 |
| Gulej, R | 1 |
| McKenzie, T | 1 |
| Lawrence, B | 1 |
| Morton, KA | 1 |
| Abdulla, ZI | 1 |
| Pennington, JL | 1 |
| Gutierrez, A | 1 |
| Skelton, MR | 3 |
| Marzuca-Nassr, GN | 1 |
| Fortes, MAS | 1 |
| Guimarães-Ferreira, L | 1 |
| Murata, GM | 1 |
| Vitzel, KF | 1 |
| Vasconcelos, DAA | 1 |
| Bassit, RA | 1 |
| Curi, R | 1 |
| Sitjà-Bobadilla, A | 1 |
| Gil-Solsona, R | 1 |
| Estensoro, I | 1 |
| Piazzon, MC | 1 |
| Martos-Sitcha, JA | 1 |
| Picard-Sánchez, A | 1 |
| Fuentes, J | 1 |
| Sancho, JV | 1 |
| Calduch-Giner, JA | 1 |
| Hernández, F | 1 |
| Pérez-Sánchez, J | 1 |
| Jensen, M | 1 |
| Müller, C | 1 |
| Choe, CU | 1 |
| Schwedhelm, E | 1 |
| Zeller, T | 1 |
| Kim, S | 3 |
| Hong, KB | 1 |
| Suh, HJ | 1 |
| Jo, K | 1 |
| Terai, K | 1 |
| Jin, D | 1 |
| Watase, K | 1 |
| Imagawa, A | 1 |
| Takai, S | 1 |
| Cacciante, F | 2 |
| Gennaro, M | 1 |
| Sagona, G | 1 |
| Mazziotti, R | 1 |
| Lupori, L | 1 |
| Cerri, E | 1 |
| Putignano, E | 3 |
| Butt, M | 2 |
| Do, MT | 2 |
| McKew, JC | 2 |
| Alessandrì, MG | 3 |
| Battini, R | 2 |
| Cioni, G | 4 |
| Pizzorusso, T | 3 |
| Baroncelli, L | 3 |
| Snow, WM | 1 |
| Cadonic, C | 1 |
| Cortes-Perez, C | 1 |
| Adlimoghaddam, A | 1 |
| Roy Chowdhury, SK | 1 |
| Thomson, E | 1 |
| Anozie, A | 1 |
| Bernstein, MJ | 1 |
| Gough, K | 1 |
| Fernyhough, P | 1 |
| Suh, M | 1 |
| Albensi, BC | 1 |
| Branovets, J | 2 |
| Karro, N | 1 |
| Barsunova, K | 1 |
| Laasmaa, M | 1 |
| Lygate, CA | 5 |
| Vendelin, M | 2 |
| Birkedal, R | 2 |
| Duran-Trio, L | 1 |
| Fernandes-Pires, G | 1 |
| Simicic, D | 1 |
| Grosse, J | 2 |
| Roux-Petronelli, C | 1 |
| Bruce, SJ | 1 |
| Binz, PA | 1 |
| Sandi, C | 2 |
| Cudalbu, C | 3 |
| Braissant, O | 4 |
| Saud, A | 1 |
| Luiz, RS | 1 |
| Leite, APO | 1 |
| Muller, CR | 1 |
| Visona, I | 1 |
| Reinecke, N | 1 |
| Silva, WH | 1 |
| Gloria, MA | 1 |
| Razvickas, CV | 1 |
| Casarini, DE | 1 |
| Schor, N | 1 |
| Müller, L | 1 |
| Power Guerra, N | 1 |
| Stenzel, J | 1 |
| Rühlmann, C | 1 |
| Lindner, T | 1 |
| Krause, BJ | 1 |
| Vollmar, B | 1 |
| Teipel, S | 1 |
| Kuhla, A | 1 |
| Liu, C | 1 |
| Wang, Z | 1 |
| Hu, X | 2 |
| Ito, H | 1 |
| Takahashi, K | 1 |
| Nakajima, M | 1 |
| Tanaka, T | 1 |
| Zhu, P | 1 |
| Li, XK | 1 |
| Chen, L | 1 |
| van Zijl, PCM | 1 |
| Wei, Z | 1 |
| Lu, H | 1 |
| Duan, W | 1 |
| Wong, PC | 1 |
| Li, T | 1 |
| Xu, J | 2 |
| Balestrino, M | 3 |
| Cavagnaro, J | 1 |
| Terse, PS | 1 |
| Gonzalez Melo, M | 1 |
| Remacle, N | 1 |
| Cudré-Cung, HP | 1 |
| Roux, C | 1 |
| Poms, M | 1 |
| Barroso, M | 1 |
| Gersting, SW | 1 |
| Feichtinger, RG | 1 |
| Mayr, JA | 1 |
| Costanzo, M | 1 |
| Caterino, M | 1 |
| Ruoppolo, M | 1 |
| Rüfenacht, V | 1 |
| Häberle, J | 1 |
| Ballhausen, D | 1 |
| Hashimoto, T | 2 |
| Shibata, K | 1 |
| Honda, K | 1 |
| Nobe, K | 1 |
| Chen, HR | 1 |
| Zhang-Brotzge, X | 1 |
| Morozov, YM | 1 |
| Li, Y | 3 |
| Wang, S | 1 |
| Zhang, HH | 1 |
| Kuan, IS | 1 |
| Fugate, EM | 1 |
| Mao, H | 2 |
| Sun, YY | 1 |
| Rakic, P | 1 |
| Lindquist, DM | 1 |
| DeGrauw, T | 1 |
| Kuan, CY | 1 |
| Rossi, L | 1 |
| Nardecchia, F | 1 |
| Pierigè, F | 1 |
| Ventura, R | 1 |
| Carducci, C | 1 |
| Leuzzi, V | 4 |
| Magnani, M | 1 |
| Cabib, S | 1 |
| Pascucci, T | 1 |
| Mao, X | 2 |
| Kelty, TJ | 1 |
| Kerr, NR | 1 |
| Childs, TE | 1 |
| Roberts, MD | 1 |
| Booth, FW | 1 |
| Ling, Q | 1 |
| Yu, X | 1 |
| Wang, T | 1 |
| Wang, SG | 1 |
| Ye, ZQ | 1 |
| Liu, JH | 2 |
| Zhang, W | 3 |
| Gu, GJ | 1 |
| Zhang, Q | 2 |
| Guo, Y | 1 |
| Wang, MY | 1 |
| Gong, QY | 1 |
| Xu, JR | 1 |
| Abudu, H | 1 |
| Aximujiang, K | 1 |
| Ahemaiti, A | 1 |
| Wu, G | 1 |
| Zhang, J | 3 |
| Yunusi, K | 2 |
| Zhou, Z | 1 |
| Nguyen, C | 1 |
| Chen, Y | 1 |
| Shaw, JL | 1 |
| Deng, Z | 1 |
| Xie, Y | 1 |
| Dawkins, J | 1 |
| Marbán, E | 1 |
| Li, D | 1 |
| Izurieta Munoz, H | 1 |
| Gonzales, EB | 1 |
| Sumien, N | 1 |
| Conotte, S | 1 |
| Tassin, A | 1 |
| Conotte, R | 1 |
| Colet, JM | 1 |
| Zouaoui Boudjeltia, K | 1 |
| Legrand, A | 1 |
| Duarte-Silva, S | 1 |
| Neves-Carvalho, A | 1 |
| Soares-Cunha, C | 1 |
| Silva, JM | 1 |
| Teixeira-Castro, A | 1 |
| Vieira, R | 1 |
| Silva-Fernandes, A | 1 |
| Maciel, P | 1 |
| Umehara, T | 1 |
| Kawai, T | 1 |
| Goto, M | 1 |
| Richards, JS | 1 |
| Shimada, M | 1 |
| Evans, E | 1 |
| Piccio, L | 1 |
| Cross, AH | 1 |
| Cooke, MB | 1 |
| Rybalka, E | 1 |
| Stathis, CG | 1 |
| Hayes, A | 1 |
| Lee, DH | 1 |
| Lee, DW | 2 |
| Kwon, JI | 1 |
| Woo, CW | 2 |
| Kim, ST | 2 |
| Lee, JS | 1 |
| Choi, CG | 1 |
| Kim, KW | 1 |
| Kim, JK | 1 |
| Woo, DC | 2 |
| Cunha, MP | 5 |
| Pazini, FL | 4 |
| Lieberknecht, V | 2 |
| Rodrigues, ALS | 1 |
| Abe, T | 1 |
| Niizuma, K | 1 |
| Kanoke, A | 1 |
| Saigusa, D | 1 |
| Saito, R | 1 |
| Uruno, A | 1 |
| Fujimura, M | 1 |
| Yamamoto, M | 1 |
| Tominaga, T | 1 |
| Chwiej, JG | 1 |
| Ciesielka, SW | 1 |
| Skoczen, AK | 1 |
| Janeczko, KJ | 1 |
| Sandt, C | 2 |
| Planeta, KL | 1 |
| Setkowicz, ZK | 1 |
| Molinaro, A | 2 |
| Sánchez-López, E | 1 |
| Kammeijer, GSM | 1 |
| Crego, AL | 1 |
| Marina, ML | 1 |
| Ramautar, R | 1 |
| Peters, DJM | 1 |
| Mayboroda, OA | 1 |
| Lemos, NE | 1 |
| Dieter, C | 1 |
| Carlessi, R | 1 |
| Rheinheimer, J | 1 |
| Brondani, LA | 1 |
| Leitão, CB | 1 |
| Bauer, AC | 1 |
| Crispim, D | 1 |
| Cella, PS | 2 |
| Marinello, PC | 2 |
| Borges, FH | 2 |
| Ribeiro, DF | 1 |
| Chimin, P | 1 |
| Testa, MTJ | 2 |
| Guirro, PB | 2 |
| Duarte, JA | 2 |
| Cecchini, R | 2 |
| Guarnier, FA | 1 |
| Deminice, R | 2 |
| Garcia, M | 1 |
| Santos-Dias, A | 1 |
| Bachi, ALL | 1 |
| Oliveira-Junior, MC | 1 |
| Andrade-Souza, AS | 1 |
| Ferreira, SC | 2 |
| Aquino-Junior, JCJ | 1 |
| Almeida, FM | 1 |
| Rigonato-Oliveira, NC | 1 |
| Oliveira, APL | 1 |
| Savio, LEB | 1 |
| Coutinho-Silva, R | 1 |
| Müller, T | 1 |
| Idzko, M | 1 |
| Siepmann, T | 1 |
| Vieira, RP | 3 |
| Lees, HJ | 1 |
| Swann, JR | 1 |
| Poucher, S | 1 |
| Holmes, E | 2 |
| Wilson, ID | 1 |
| Nicholson, JK | 1 |
| Rackayová, V | 1 |
| Pierzchala, K | 1 |
| McLin, VA | 1 |
| Torok, ZA | 1 |
| Busekrus, RB | 1 |
| Hydock, DS | 1 |
| Brito, WAS | 1 |
| Cecchini, AL | 1 |
| Bortoluzzi, VT | 1 |
| Brust, L | 1 |
| Preissler, T | 1 |
| de Franceschi, ID | 1 |
| Wannmacher, CMD | 1 |
| Kantarci, K | 1 |
| Hautman, ER | 1 |
| Kokenge, AN | 1 |
| Udobi, KC | 1 |
| Williams, MT | 2 |
| Vorhees, CV | 2 |
| Fu, W | 1 |
| Zheng, Z | 1 |
| Zhuang, W | 1 |
| Chen, D | 1 |
| Wang, X | 4 |
| Sun, X | 1 |
| Sepp, M | 1 |
| Kotlyarova, S | 1 |
| Jepihhina, N | 1 |
| Sokolova, N | 1 |
| Aksentijevic, D | 2 |
| Neubauer, S | 4 |
| Kutorasinska, J | 1 |
| Setkowicz, Z | 1 |
| Janeczko, K | 1 |
| Dumas, P | 1 |
| Chwiej, J | 1 |
| Hou, Z | 2 |
| Zhang, Z | 2 |
| Meng, H | 1 |
| Lin, X | 2 |
| Sun, B | 1 |
| Lei, H | 2 |
| Fang, K | 1 |
| Fang, F | 1 |
| Liu, M | 1 |
| Liu, S | 2 |
| Li, N | 1 |
| Hu, DH | 1 |
| Wang, YJ | 1 |
| Hu, XL | 1 |
| Zhang, Y | 2 |
| Li, XQ | 1 |
| Shi, JH | 1 |
| Bai, XZ | 1 |
| Cai, WX | 1 |
| Francis, BM | 1 |
| Yang, J | 1 |
| Song, BJ | 1 |
| Gupta, S | 1 |
| Maj, M | 1 |
| Bazinet, RP | 1 |
| Robinson, B | 1 |
| Mount, HT | 1 |
| Li, P | 2 |
| Bledsoe, G | 1 |
| Yang, ZR | 1 |
| Fan, H | 1 |
| Chao, L | 1 |
| Chao, J | 1 |
| dos Santos, FS | 1 |
| da Silva, LA | 1 |
| Pochapski, JA | 1 |
| Raczenski, A | 1 |
| da Silva, WC | 1 |
| Grassiolli, S | 1 |
| Malfatti, CR | 2 |
| Liu, X | 1 |
| Wang, L | 1 |
| Peng, D | 1 |
| Wang, Y | 3 |
| Ren, M | 1 |
| Liso Navarro, AA | 1 |
| Sikoglu, EM | 1 |
| Heinze, CR | 1 |
| Rogan, RC | 1 |
| Russell, VA | 1 |
| King, JA | 1 |
| Moore, CM | 1 |
| Tran, C | 1 |
| Yazdanpanah, M | 1 |
| Kyriakopoulou, L | 1 |
| Levandovskiy, V | 1 |
| Zahid, H | 1 |
| Naufer, A | 1 |
| Isbrandt, D | 2 |
| Schulze, A | 1 |
| Budni, J | 1 |
| Oliveira, Á | 3 |
| Rosa, JM | 3 |
| Lopes, MW | 1 |
| Leal, RB | 1 |
| Rodrigues, AL | 4 |
| Zahr, NM | 1 |
| Alt, C | 1 |
| Mayer, D | 1 |
| Rohlfing, T | 1 |
| Manning-Bog, A | 1 |
| Luong, R | 1 |
| Sullivan, EV | 1 |
| Pfefferbaum, A | 1 |
| Khowailed, A | 1 |
| Younan, SM | 1 |
| Ashour, H | 1 |
| Kamel, AE | 1 |
| Sharawy, N | 1 |
| Robertson, NJ | 1 |
| Thayyil, S | 1 |
| Cady, EB | 1 |
| Raivich, G | 1 |
| Ihara, K | 1 |
| Asanuma, K | 1 |
| Fukuda, T | 1 |
| Ohwada, S | 1 |
| Yoshida, M | 1 |
| Nishimori, K | 1 |
| Xu, L | 1 |
| Wang, CY | 1 |
| Lv, L | 1 |
| Liu, KX | 1 |
| Sun, HJ | 1 |
| Han, GZ | 1 |
| Lee, ES | 1 |
| Baek, SH | 1 |
| Ahn, SY | 1 |
| Na, KY | 1 |
| Chae, DW | 1 |
| Chin, HJ | 1 |
| Li, CX | 1 |
| Zhang, X | 3 |
| Komery, A | 1 |
| Herndon, JG | 1 |
| Novembre, FJ | 1 |
| Iqbal, S | 2 |
| Ali, M | 2 |
| Iqbal, F | 3 |
| Allah Yar, R | 1 |
| Akbar, A | 1 |
| Yao, L | 1 |
| Sun, YT | 1 |
| Sun, W | 1 |
| Xu, TH | 1 |
| Ren, C | 1 |
| Fan, X | 1 |
| Sun, L | 1 |
| Liu, LL | 1 |
| Feng, JM | 1 |
| Ma, JF | 1 |
| Wang, LN | 1 |
| Mosha, G | 1 |
| Nurmaimaiti, A | 1 |
| Abudula, M | 1 |
| Huang, J | 1 |
| Wu, WE | 1 |
| Babb, JS | 1 |
| Tal, A | 1 |
| Kirov, II | 1 |
| George, AE | 1 |
| Ratai, EM | 4 |
| Gonzalez, RG | 5 |
| Gonen, O | 1 |
| Doert, A | 1 |
| Pilatus, U | 1 |
| Zanella, F | 1 |
| Müller, WE | 1 |
| Eckert, GP | 1 |
| Praet, J | 1 |
| Orije, J | 1 |
| Kara, F | 1 |
| Guglielmetti, C | 1 |
| Santermans, E | 1 |
| Daans, J | 1 |
| Hens, N | 1 |
| Verhoye, M | 1 |
| Berneman, Z | 1 |
| Ponsaerts, P | 1 |
| Van der Linden, A | 1 |
| Shrot, S | 1 |
| Tauber, M | 1 |
| Shiyovich, A | 1 |
| Milk, N | 1 |
| Rosman, Y | 1 |
| Eisenkraft, A | 1 |
| Kadar, T | 1 |
| Kassirer, M | 1 |
| Cohen, Y | 1 |
| Ozturk, SA | 1 |
| Ceylan, C | 1 |
| Serel, TA | 1 |
| Doluoglu, OG | 1 |
| Soyupek, AS | 1 |
| Guzel, A | 1 |
| Özorak, A | 1 |
| Uz, E | 1 |
| Savas, HB | 1 |
| Baspinar, S | 1 |
| Yu, C | 1 |
| Qi, D | 1 |
| Sun, JF | 1 |
| Fan, HY | 1 |
| Tian, R | 1 |
| Han, L | 1 |
| Hao, S | 1 |
| Zhu, Z | 1 |
| Tao, X | 1 |
| Liu, B | 1 |
| Takanashi, J | 1 |
| Zervou, S | 2 |
| Whittington, HJ | 2 |
| Russell, AJ | 1 |
| Freire Royes, LF | 1 |
| Cassol, G | 1 |
| Zeng, J | 1 |
| Huang, X | 1 |
| Zhou, L | 1 |
| Tan, Y | 1 |
| Hu, C | 1 |
| Niu, J | 1 |
| Wang, H | 1 |
| Yin, P | 1 |
| Colla, AR | 1 |
| Bender, A | 2 |
| Klopstock, T | 2 |
| McAndrew, DJ | 1 |
| Cross, RL | 1 |
| Cordero, MI | 1 |
| Just, N | 1 |
| Poirier, GL | 1 |
| Hanna-El-Daher, L | 1 |
| LaRosa, DA | 2 |
| Ellery, SJ | 3 |
| Parkington, HC | 1 |
| Snow, RJ | 3 |
| Walker, DW | 4 |
| Dickinson, H | 4 |
| Yoon, KJ | 1 |
| Lee, YT | 1 |
| Chae, SW | 1 |
| Park, CR | 1 |
| Kim, DY | 1 |
| Tang, Y | 1 |
| Zhang, L | 1 |
| Yang, YY | 1 |
| Zhao, YL | 1 |
| Fu, P | 1 |
| Wang, P | 1 |
| Wang, W | 1 |
| Shi, Q | 1 |
| Zhao, L | 1 |
| Mei, F | 1 |
| Li, C | 1 |
| Zuo, T | 1 |
| He, X | 1 |
| Napoli, D | 1 |
| Tola, J | 1 |
| Romariz, SA | 1 |
| Paiva, DS | 1 |
| Galindo, LT | 1 |
| Barnabé, GF | 1 |
| Guedes, VA | 1 |
| Borlongan, CV | 1 |
| Longo, BM | 1 |
| Pearce, PS | 1 |
| Wu, Y | 1 |
| Rapuano, A | 1 |
| Kelly, KM | 1 |
| de Lanerolle, N | 1 |
| Pan, JW | 1 |
| Hernández Cruz, A | 1 |
| Garcia-Jimenez, S | 1 |
| Zucatelli Mendonça, R | 1 |
| Petricevich, VL | 1 |
| Schubert, GA | 1 |
| Poli, S | 1 |
| Schilling, L | 1 |
| Heiland, S | 1 |
| Thomé, C | 1 |
| Doi, K | 1 |
| Leelahavanichkul, A | 1 |
| Sidransky, KL | 1 |
| Zhou, H | 1 |
| Qin, Y | 1 |
| Eisner, C | 1 |
| Schnermann, J | 1 |
| Yuen, PS | 1 |
| Star, RA | 1 |
| Tarnopolsky, MA | 3 |
| Klein, AM | 2 |
| Ferrante, RJ | 5 |
| Munkeby, BH | 1 |
| De Lange, C | 1 |
| Emblem, KE | 1 |
| Bjørnerud, A | 1 |
| Kro, GA | 1 |
| Andresen, J | 1 |
| Winther-Larssen, EH | 1 |
| Løberg, EM | 1 |
| Hald, JK | 1 |
| Valastro, B | 1 |
| Dekundy, A | 1 |
| Danysz, W | 1 |
| Quack, G | 1 |
| Lee, K | 1 |
| Min, BG | 1 |
| Mun, CH | 1 |
| Lee, SR | 1 |
| Won, YS | 1 |
| Immonen, RJ | 1 |
| Kharatishvili, I | 1 |
| Niskanen, JP | 1 |
| Gröhn, H | 1 |
| Pitkänen, A | 1 |
| Gröhn, OH | 1 |
| Ma, Z | 1 |
| Wang, SJ | 1 |
| Li, CF | 1 |
| Ma, XX | 1 |
| Gu, T | 1 |
| Ward, BC | 1 |
| Kolodny, NH | 1 |
| Nag, N | 1 |
| Berger-Sweeney, JE | 1 |
| Baik, SK | 1 |
| Kim, YW | 1 |
| Kim, HJ | 1 |
| Lee, JW | 1 |
| Cho, BM | 1 |
| Kim, DH | 1 |
| Choi, SH | 1 |
| Lee, SH | 2 |
| Chang, KH | 1 |
| Kondziella, D | 1 |
| Eyjolfsson, EM | 1 |
| Saether, O | 2 |
| Sonnewald, U | 2 |
| Risa, O | 1 |
| Palkovits, M | 1 |
| Sebekova, K | 2 |
| Gallatz, K | 1 |
| Boor, P | 1 |
| Klassen, A | 1 |
| Bahner, U | 1 |
| Heidland, A | 1 |
| Yang, L | 4 |
| Calingasan, NY | 3 |
| Wille, EJ | 1 |
| Cormier, K | 1 |
| Smith, K | 1 |
| Beal, MF | 8 |
| Perasso, L | 2 |
| Adriano, E | 1 |
| Ruggeri, P | 1 |
| Burov, SV | 1 |
| Gandolfo, C | 2 |
| Pilkenton, SJ | 1 |
| Greco, JB | 3 |
| Lentz, MR | 4 |
| Bombardier, JP | 1 |
| Turk, KW | 1 |
| He, J | 2 |
| Joo, CG | 1 |
| Lee, V | 2 |
| Westmoreland, S | 1 |
| Halpern, E | 3 |
| Lackner, AA | 3 |
| Duarte, AC | 1 |
| Santos, AB | 2 |
| Medeiros, MC | 2 |
| Mauad, T | 1 |
| Martins, MA | 2 |
| Carvalho, CR | 2 |
| Dolhnikoff, M | 2 |
| Lescot, T | 1 |
| Fulla-Oller, L | 2 |
| Po, C | 1 |
| Chen, XR | 1 |
| Puybasset, L | 1 |
| Gillet, B | 1 |
| Plotkine, M | 1 |
| Meric, P | 1 |
| Marchand-Leroux, C | 1 |
| Allen, PJ | 2 |
| D'Anci, KE | 2 |
| Kanarek, RB | 2 |
| Renshaw, PF | 2 |
| Zheng, W | 1 |
| Honmou, O | 1 |
| Miyata, K | 1 |
| Harada, K | 1 |
| Suzuki, J | 1 |
| Liu, H | 1 |
| Houkin, K | 1 |
| Hamada, H | 1 |
| Kocsis, JD | 1 |
| Choi, JK | 1 |
| Küstermann, E | 1 |
| Dedeoglu, A | 3 |
| Jenkins, BG | 3 |
| Qian, J | 1 |
| Herrera, JJ | 1 |
| Narayana, PA | 1 |
| Acosta, ML | 1 |
| Shin, YS | 1 |
| Ready, S | 1 |
| Fletcher, EL | 1 |
| Christie, DL | 1 |
| Kalloniatis, M | 1 |
| Inácio, CM | 1 |
| Dietz, UA | 1 |
| Malafaia, O | 1 |
| Ribas Filho, JM | 1 |
| Nassif, PA | 1 |
| Czeczko, NG | 1 |
| Marcondes, CA | 1 |
| Lau, DH | 1 |
| Mackenzie, L | 1 |
| Rajendram, A | 1 |
| Psaltis, PJ | 1 |
| Kelly, DR | 1 |
| Spyropoulos, P | 1 |
| Olakkengil, SA | 1 |
| Russell, CH | 1 |
| Brooks, AG | 1 |
| Faull, RJ | 1 |
| Saint, DA | 1 |
| Kelly, DJ | 1 |
| Rao, MM | 1 |
| Worthley, SG | 1 |
| Sanders, P | 1 |
| Teixeira, AR | 1 |
| Machado, MC | 1 |
| Kubrusly, MS | 1 |
| Molan, NT | 1 |
| Bellodi-Privato, M | 1 |
| Leite, KR | 1 |
| D'Albuquerque, LA | 1 |
| Kim, SY | 2 |
| Lee, YJ | 1 |
| Kim, H | 1 |
| Choi, CB | 2 |
| Chae, JH | 1 |
| Choe, BY | 2 |
| Kuzyk, A | 1 |
| Kastyak, M | 1 |
| Agrawal, V | 1 |
| Gallant, M | 1 |
| Sivakumar, G | 1 |
| Rak, M | 1 |
| Del Bigio, MR | 1 |
| Westaway, D | 1 |
| Julian, R | 1 |
| Gough, KM | 1 |
| Xu, W | 1 |
| Zhan, Y | 1 |
| Huang, W | 2 |
| Zhang, S | 1 |
| Kolling, J | 1 |
| Wyse, AT | 1 |
| LeBleu, V | 1 |
| Sund, M | 1 |
| Sugimoto, H | 1 |
| Birrane, G | 1 |
| Kanasaki, K | 1 |
| Finan, E | 1 |
| Miller, CA | 1 |
| Gattone, VH | 1 |
| McLaughlin, H | 1 |
| Shield, CF | 1 |
| Kalluri, R | 1 |
| Kim, DW | 1 |
| Yeo, SI | 1 |
| Ryu, HJ | 1 |
| Kim, JE | 1 |
| Song, HK | 1 |
| Kwon, OS | 1 |
| Choi, SY | 1 |
| Kang, TC | 1 |
| Jahng, GH | 1 |
| Kim, HY | 1 |
| Ryu, KN | 1 |
| Yang, DM | 1 |
| Yim, SV | 1 |
| Choi, WS | 1 |
| Zhao, LC | 1 |
| Zhang, XD | 1 |
| Liao, SX | 1 |
| Gao, HC | 1 |
| Wang, HY | 1 |
| Lin, DH | 1 |
| Toledo, AC | 1 |
| Hage, M | 1 |
| Schaefer, TL | 1 |
| Graham, DL | 1 |
| Degrauw, TJ | 1 |
| Clark, JF | 1 |
| Elstner, M | 1 |
| Lin, YS | 1 |
| Chen, CM | 1 |
| Soong, BW | 1 |
| Wu, YR | 1 |
| Chen, HM | 1 |
| Yeh, WY | 1 |
| Wu, DR | 1 |
| Lin, YJ | 1 |
| Poon, PW | 1 |
| Cheng, ML | 1 |
| Wang, CH | 1 |
| Chern, Y | 1 |
| Horecký, J | 1 |
| Gvozdjáková, A | 1 |
| Kucharská, J | 1 |
| Obrenovich, ME | 1 |
| Palacios, HH | 1 |
| Vančová, O | 1 |
| Aliev, G | 1 |
| Ireland, Z | 2 |
| Castillo-Melendez, M | 1 |
| Snow, R | 2 |
| Palani, S | 1 |
| Raja, S | 1 |
| Kumar, RP | 1 |
| Selvaraj, R | 1 |
| Kumar, BS | 1 |
| Caliskan, B | 1 |
| Guven, A | 1 |
| Ozler, M | 1 |
| Cayci, T | 1 |
| Ozcan, A | 1 |
| Bedir, O | 1 |
| Surer, I | 1 |
| Korkmaz, A | 1 |
| Liu, W | 1 |
| Shu, XJ | 1 |
| Chen, FY | 1 |
| Zhu, C | 1 |
| Sun, XH | 1 |
| Liu, LJ | 1 |
| Ai, YX | 1 |
| Li, YG | 1 |
| Zhao, H | 1 |
| Saraiva, AL | 1 |
| Ferreira, AP | 1 |
| Silva, LF | 1 |
| Hoffmann, MS | 1 |
| Dutra, FD | 1 |
| Furian, AF | 3 |
| Oliveira, MS | 3 |
| Fighera, MR | 3 |
| Royes, LF | 3 |
| Naia, L | 1 |
| Ribeiro, MJ | 1 |
| Rego, AC | 1 |
| Sultan, MT | 1 |
| Butt, MS | 1 |
| Ahmad, RS | 1 |
| Pasha, I | 1 |
| Ahmad, AN | 1 |
| Qayyum, MM | 1 |
| Xi, G | 1 |
| Hui, J | 1 |
| Teng, G | 1 |
| Chan, KC | 1 |
| Wu, EX | 1 |
| Nie, B | 1 |
| Shan, B | 1 |
| Li, L | 1 |
| Reynolds, GP | 1 |
| de Andrade, RB | 1 |
| Gemelli, T | 1 |
| Rojas, DB | 1 |
| Funchal, C | 1 |
| Dutra-Filho, CS | 1 |
| Wannmacher, CM | 1 |
| Esteras, N | 1 |
| Alquézar, C | 1 |
| Bartolomé, F | 1 |
| Antequera, D | 1 |
| Barrios, L | 2 |
| Carro, E | 1 |
| Cerdán, S | 2 |
| Martín-Requero, A | 1 |
| Lee, EM | 1 |
| Park, GY | 1 |
| Im, KC | 1 |
| Chung, JH | 1 |
| Kim, KS | 1 |
| Kim, JS | 1 |
| Shon, YM | 1 |
| Kim, YI | 1 |
| Kang, JK | 1 |
| Madonna, R | 1 |
| Delli Pizzi, S | 1 |
| Di Donato, L | 1 |
| Mariotti, A | 1 |
| Di Carlo, L | 1 |
| D'Ugo, E | 1 |
| Teberino, MA | 1 |
| Merla, A | 1 |
| Tartaro, A | 1 |
| De Caterina, R | 1 |
| Machado, DG | 2 |
| Capra, JC | 1 |
| Jacinto, J | 1 |
| Bettio, LE | 2 |
| Li, YC | 1 |
| Tsai, SH | 1 |
| Chen, SM | 1 |
| Chang, YM | 1 |
| Huang, TC | 1 |
| Huang, YP | 1 |
| Chang, CT | 1 |
| Lee, JA | 1 |
| Chen, SQ | 1 |
| Cai, Q | 1 |
| Shen, YY | 1 |
| Wang, PJ | 1 |
| Teng, GJ | 1 |
| Zang, FC | 1 |
| Bohl, S | 1 |
| ten Hove, M | 1 |
| Faller, KM | 1 |
| Ostrowski, PJ | 1 |
| Medway, DJ | 1 |
| Sebag-Montefiore, L | 1 |
| Wallis, J | 1 |
| Clarke, K | 1 |
| Watkins, H | 1 |
| Schneider, JE | 1 |
| Nilsen, LH | 1 |
| Melø, TM | 1 |
| Witter, MP | 1 |
| Haris, M | 1 |
| Singh, A | 1 |
| Cai, K | 1 |
| Nath, K | 1 |
| Crescenzi, R | 1 |
| Kogan, F | 1 |
| Hariharan, H | 1 |
| Reddy, R | 1 |
| Jian, H | 1 |
| Yi-Fang, W | 1 |
| Qi, L | 1 |
| Xiao-Song, H | 1 |
| Gui-Yun, Z | 1 |
| Mastrangelo, M | 1 |
| Kett, MM | 1 |
| Wang, HP | 1 |
| Liu, CW | 1 |
| Chang, HW | 1 |
| Tsai, JW | 1 |
| Sung, YZ | 1 |
| Chang, LC | 1 |
| Sarzi, E | 1 |
| Angebault, C | 1 |
| Seveno, M | 1 |
| Gueguen, N | 1 |
| Chaix, B | 1 |
| Bielicki, G | 1 |
| Boddaert, N | 1 |
| Mausset-Bonnefont, AL | 1 |
| Cazevieille, C | 1 |
| Rigau, V | 1 |
| Renou, JP | 1 |
| Wang, J | 1 |
| Delettre, C | 1 |
| Brabet, P | 1 |
| Puel, JL | 1 |
| Hamel, CP | 1 |
| Reynier, P | 1 |
| Lenaers, G | 1 |
| van Duijn, S | 1 |
| Nabuurs, RJ | 1 |
| van Duinen, SG | 1 |
| Natté, R | 1 |
| van Buchem, MA | 1 |
| Alia, A | 1 |
| Newman, SJ | 1 |
| Johnson, R | 1 |
| Sears, W | 1 |
| Wilcock, B | 1 |
| Pascuzzi, RM | 1 |
| Hausmann, ON | 1 |
| Fouad, K | 1 |
| Wallimann, T | 3 |
| Schwab, ME | 1 |
| Narayanan, M | 1 |
| Friedlander, RM | 1 |
| Albrecht, EW | 1 |
| van Goor, H | 1 |
| Smit-van Oosten, A | 1 |
| Stegeman, CA | 1 |
| Podell, M | 1 |
| Hadjiconstantinou, M | 1 |
| Smith, MA | 1 |
| Neff, NH | 1 |
| da Silva, LG | 1 |
| Schneider, PH | 1 |
| Braga, AL | 1 |
| Wajner, M | 2 |
| Mello, CF | 2 |
| Kubilus, JK | 1 |
| Ferrante, KL | 2 |
| Hersch, SM | 1 |
| Turnbull, J | 1 |
| da Silva, S | 1 |
| Jiang, F | 1 |
| Bates, GP | 2 |
| Hockly, E | 2 |
| Surendran, S | 1 |
| Rady, PL | 1 |
| Michals-Matalon, K | 1 |
| Quast, MJ | 1 |
| Rassin, DK | 1 |
| Campbell, GA | 1 |
| Ezell, EL | 1 |
| Wei, J | 1 |
| Tyring, SK | 1 |
| Szucs, S | 1 |
| Matalon, R | 1 |
| Baker, SK | 1 |
| Vielhaber, S | 1 |
| Kudin, AP | 1 |
| Kudina, TA | 1 |
| Stiller, D | 1 |
| Scheich, H | 1 |
| Schoenfeld, A | 1 |
| Feistner, H | 1 |
| Heinze, HJ | 1 |
| Elger, CE | 1 |
| Kunz, WS | 1 |
| Klivenyi, P | 3 |
| Gardian, G | 2 |
| Kiessling, F | 1 |
| Huber, PE | 1 |
| Grobholz, R | 1 |
| Heilmann, M | 1 |
| Meding, J | 1 |
| Lichy, MP | 1 |
| Fink, C | 1 |
| Krix, M | 1 |
| Peschke, P | 1 |
| Schlemmer, HP | 1 |
| Berger, R | 1 |
| Middelanis, J | 1 |
| Vaihinger, HM | 1 |
| Mies, G | 1 |
| Wilken, B | 1 |
| Jensen, A | 1 |
| Kiaei, M | 1 |
| Cloak, CC | 1 |
| Chang, L | 1 |
| Ernst, T | 1 |
| Barr, MC | 1 |
| Huitron-Resendiz, S | 1 |
| Sanchez-Alavez, M | 1 |
| Phillips, TR | 1 |
| Henriksen, S | 1 |
| Choi, EW | 1 |
| Lee, CW | 1 |
| Fuller, RA | 1 |
| Westmoreland, SV | 3 |
| Ratai, E | 1 |
| Kim, JP | 2 |
| Sehgal, PK | 1 |
| Masliah, E | 2 |
| Kim, EH | 1 |
| Choi, KS | 1 |
| Lee, KW | 1 |
| Suh, JG | 1 |
| Choi, YK | 1 |
| Hyun, BH | 1 |
| Ishikawa, A | 1 |
| Namikawa, T | 1 |
| Lee, CH | 2 |
| Ellis, AC | 1 |
| Rosenfeld, J | 1 |
| Shirayama, Y | 1 |
| Takahashi, S | 1 |
| Minabe, Y | 1 |
| Ogino, T | 1 |
| Koga, Y | 1 |
| Takahashi, H | 1 |
| Oikawa, D | 1 |
| Tachibana, T | 1 |
| Denbow, DM | 1 |
| Furuse, M | 1 |
| Torremans, A | 1 |
| Marescau, B | 1 |
| Possemiers, I | 1 |
| Van Dam, D | 1 |
| D'Hooge, R | 1 |
| De Deyn, PP | 1 |
| Koch, M | 1 |
| Joosten, SA | 1 |
| Mengel, M | 1 |
| van Kooten, C | 1 |
| Paul, LC | 1 |
| Nashan, B | 1 |
| Nelson, JA | 1 |
| Dou, H | 1 |
| Ellison, B | 1 |
| Uberti, M | 1 |
| Xiong, H | 1 |
| Anderson, E | 1 |
| Mellon, M | 1 |
| Gelbard, HA | 1 |
| Boska, M | 1 |
| Gendelman, HE | 1 |
| Davey, RA | 1 |
| Morris, HA | 1 |
| van Putte, BP | 1 |
| Huisman, A | 1 |
| Hendriks, JM | 1 |
| van Schil, PE | 1 |
| van Boven, WJ | 1 |
| Schramel, F | 1 |
| Nijkamp, F | 1 |
| Folkerts, G | 1 |
| Akira, K | 1 |
| Imachi, M | 1 |
| Ferreira, LG | 1 |
| De Toledo Bergamaschi, C | 1 |
| Lazaretti-Castro, M | 1 |
| Heilberg, IP | 1 |
| Pears, MR | 1 |
| Cooper, JD | 1 |
| Mitchison, HM | 1 |
| Mortishire-Smith, RJ | 1 |
| Pearce, DA | 1 |
| Griffin, JL | 3 |
| Yang, Y | 1 |
| Wu, Z | 1 |
| Kuo, YM | 1 |
| Zhou, B | 1 |
| Vasques, V | 1 |
| Brinco, F | 1 |
| Viegas, CM | 1 |
| Kawamura, K | 1 |
| Okada, S | 1 |
| Li, B | 1 |
| Suwa, M | 1 |
| Yao, J | 1 |
| Morioka, T | 1 |
| Gejyo, F | 1 |
| Oite, T | 1 |
| Op't Eijnde, B | 1 |
| Jijakli, H | 1 |
| Hespel, P | 1 |
| Malaisse, WJ | 1 |
| Prass, K | 1 |
| Royl, G | 1 |
| Lindauer, U | 1 |
| Freyer, D | 1 |
| Megow, D | 1 |
| Dirnagl, U | 1 |
| Stöckler-Ipsiroglu, G | 1 |
| Priller, J | 1 |
| Guadagnini, D | 1 |
| Gontijo, JA | 1 |
| Baylis, C | 1 |
| Lensman, M | 1 |
| Korzhevskii, DE | 1 |
| Mourovets, VO | 1 |
| Kostkin, VB | 1 |
| Izvarina, N | 1 |
| Otellin, VA | 1 |
| Polenov, SA | 1 |
| Pundik, S | 1 |
| Robinson, S | 1 |
| Lust, WD | 1 |
| Zechel, J | 1 |
| Buczek, M | 1 |
| Selman, WR | 1 |
| Pasdois, P | 1 |
| Quinlan, CL | 1 |
| Rissa, A | 1 |
| Tariosse, L | 1 |
| Vinassa, B | 1 |
| Costa, AD | 1 |
| Pierre, SV | 1 |
| Dos Santos, P | 1 |
| Garlid, KD | 1 |
| Lorentzon, M | 1 |
| Råmunddal, T | 1 |
| Bollano, E | 1 |
| Soussi, B | 1 |
| Waagstein, F | 1 |
| Omerovic, E | 1 |
| Broom, KA | 1 |
| Anthony, DC | 1 |
| Lowe, JP | 1 |
| Scott, H | 1 |
| Blamire, AM | 1 |
| Styles, P | 1 |
| Perry, VH | 1 |
| Sibson, NR | 1 |
| McClure, WC | 1 |
| Rabon, RE | 1 |
| Ogawa, H | 1 |
| Tseng, BS | 1 |
| Pascual, JM | 1 |
| Solivera, J | 1 |
| Prieto, R | 1 |
| López-Larrubia, P | 1 |
| Roda, JM | 1 |
| Hiremath, GK | 1 |
| Najm, IM | 2 |
| Magni, DV | 1 |
| Fiorenza, NG | 1 |
| Ferreira, J | 1 |
| Chen, YH | 1 |
| Liang, YX | 1 |
| Chen, LQ | 1 |
| Liang, JJ | 1 |
| Qiu, J | 1 |
| Li, WL | 1 |
| Hu, JB | 1 |
| Xie, KJ | 1 |
| Zhong, WD | 1 |
| Chen, LZ | 1 |
| Zheng, KL | 1 |
| Kaplan, M | 1 |
| Atakan, IH | 1 |
| Aydoğdu, N | 1 |
| Aktoz, T | 1 |
| Ozpuyan, F | 1 |
| Seren, G | 1 |
| Tokuç, B | 1 |
| Inci, O | 1 |
| Gwak, M | 1 |
| Park, P | 1 |
| Kim, K | 1 |
| Lim, K | 1 |
| Jeong, S | 1 |
| Baek, C | 1 |
| Lee, J | 1 |
| Lan, MJ | 1 |
| McLoughlin, GA | 1 |
| Tsang, TM | 1 |
| Huang, JT | 1 |
| Yuan, P | 1 |
| Manji, H | 1 |
| Bahn, S | 1 |
| Halpern, EF | 1 |
| Torres, G | 1 |
| Hallas, BH | 1 |
| Gross, KW | 1 |
| Spernyak, JA | 1 |
| Horowitz, JM | 1 |
| Yang, TT | 1 |
| Li, ZW | 1 |
| Liu, L | 1 |
| Zheng, N | 1 |
| van der Wijk, J | 1 |
| Rijkmans, BG | 1 |
| Kootstra, G | 1 |
| Liao, R | 1 |
| Nascimben, L | 1 |
| Friedrich, J | 1 |
| Gwathmey, JK | 1 |
| Ingwall, JS | 1 |
| Matthews, RT | 2 |
| Rosen, BR | 1 |
| Kaddurah-Daouk, R | 3 |
| Michael O'Donnell, J | 1 |
| Narayan, P | 1 |
| Bailey, MQ | 1 |
| Abduljalil, AM | 1 |
| Altschuld, RA | 1 |
| McCune, SA | 1 |
| Robitaille, PM | 1 |
| Gayan-Ramirez, G | 1 |
| Decramer, M | 1 |
| Cecil, KM | 1 |
| Lenkinski, RE | 1 |
| Meaney, DF | 1 |
| McIntosh, TK | 1 |
| Smith, DH | 1 |
| Nonaka, M | 1 |
| Yoshimine, T | 1 |
| Kohmura, E | 1 |
| Wakayama, A | 1 |
| Yamashita, T | 1 |
| Hayakawa, T | 1 |
| Pioro, EP | 1 |
| Moore, JK | 1 |
| Ng, TC | 2 |
| Trapp, BD | 1 |
| Klinkosz, B | 1 |
| Mitsumoto, H | 1 |
| Bogdanov, MB | 2 |
| Andreassen, OA | 2 |
| Mueller, G | 1 |
| Wermer, M | 1 |
| Ishikawa, H | 1 |
| Michaelis, T | 1 |
| Wick, M | 1 |
| Fujimori, H | 1 |
| Matsumura, A | 1 |
| Frahm, J | 1 |
| Remkes, H | 1 |
| Spindler, M | 1 |
| Horn, M | 1 |
| Wiesmann, F | 1 |
| Prestle, J | 1 |
| Walzel, B | 1 |
| Ertl, G | 1 |
| Hasenfuss, G | 1 |
| Maton, BM | 1 |
| Lüders, HO | 1 |
| Galdzicki, Z | 1 |
| van Gelderen, P | 1 |
| Balbo, A | 1 |
| Chikhale, EG | 1 |
| Schapiro, MB | 1 |
| Rapoport, SI | 1 |
| Sabatini, S | 1 |
| Yao, FS | 1 |
| Caserta, MT | 1 |
| Wyrwicz, AM | 1 |
| Sakemi, T | 1 |
| Ikeda, Y | 1 |
| Shimazu, K | 1 |
| Uesugi, T | 1 |
| Yokoo, T | 1 |
| Ohashi, T | 1 |
| Utsunomiya, Y | 1 |
| Shen, JS | 1 |
| Hisada, Y | 1 |
| Eto, Y | 1 |
| Kawamura, T | 1 |
| Hosoya, T | 1 |
| Ikeda, K | 1 |
| Iwasaki, Y | 1 |
| Kinoshita, M | 1 |
| Zoll, J | 1 |
| Ventura-Clapier, R | 1 |
| Serrurier, B | 1 |
| Bigard, AX | 1 |
| Smith, DL | 1 |
| Portier, R | 1 |
| Woodman, B | 1 |
| Mahal, A | 1 |
| Klunk, WE | 1 |
| Li, XJ | 1 |
| Wanker, E | 1 |
| Murray, KD | 1 |
| Zheng, F | 1 |
| Huang, Q | 1 |
| Vona-Davis, L | 1 |
| Wearden, PD | 1 |
| Karne, NH | 1 |
| Hill, RC | 1 |
| Opie, LH | 1 |
| Bruyneel, K | 1 |
| Owen, P | 1 |
| Isselhard, W | 1 |
| Geppert, E | 1 |
| Menge, M | 1 |
| Lauterjung, KL | 1 |
| Vogel, W | 1 |
| Witte, J | 1 |
| Heugel, E | 1 |
| Matsukawa, W | 1 |
| Hara, S | 1 |
| Yoshida, F | 1 |
| Suzuki, N | 1 |
| Fukatsu, A | 1 |
| Yuzawa, Y | 1 |
| Sakamoto, N | 1 |
| Matsuo, S | 1 |
| Law, WR | 1 |
| Nadkarni, VM | 1 |
| Fletcher, MA | 1 |
| Nevola, JJ | 1 |
| Eckstein, JM | 1 |
| Quance, J | 1 |
| McKenna, TM | 1 |
| Williams, TJ | 1 |
| Magnusson, M | 1 |
| Magnusson, KE | 1 |
| Sundqvist, T | 1 |
| Denneberg, T | 1 |
| Milner, LS | 1 |
| Wei, SH | 1 |
| Houser, MT | 1 |
| Matsuo, H | 1 |
| Thliveris, JA | 1 |
| Yatscoff, RW | 1 |
| Lukowski, MP | 1 |
| Copeland, KR | 1 |
| Jeffery, JR | 1 |
| Murphy, GF | 1 |
| Groggel, GC | 1 |
| Terreros, DA | 1 |
| Shimamura, T | 1 |
| Thurston, JH | 1 |
| Hauhart, RE | 1 |
| Nelson, JS | 1 |
| Hirsch, DJ | 1 |
| Coleman, HN | 1 |
| Taylor, RR | 1 |
| Pool, PE | 1 |
| Whipple, GH | 1 |
| Covell, JW | 1 |
| Ross, J | 1 |
| Braunwald, E | 1 |
| Harvey, JC | 1 |
| Straub, E | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Adjuvant Effects of Vitamin A and Vitamin D Supplementation on Treatment of Children With ADHD:A Randomized, Double Blind, Placebo-controlled, Multicentric Trial.[NCT04284059] | Phase 4 | 504 participants (Anticipated) | Interventional | 2021-02-25 | Recruiting | ||
| Optimising the Duration of Cooling Therapy in Mild Neonatal Encephalopathy[NCT03409770] | 140 participants (Anticipated) | Interventional | 2019-10-10 | Active, not recruiting | |||
| The Effect of Creatine Monohydrate on Persistent Post-concussive Symptoms - a Pilot Study Protocol[NCT05562232] | 45 participants (Anticipated) | Interventional | 2022-10-01 | Not yet recruiting | |||
| Creatine Augmentation in Female & Male Veterans With Selective Serotonin Reuptake Inhibitor-Resistant Major Depressive Disorder[NCT01175616] | Phase 4 | 0 participants (Actual) | Interventional | 2012-09-30 | Withdrawn (stopped due to Study withdrawn from ClinicalTrials.gov.) | ||
| Phase II Combination Therapy Selection Trial in Amyotrophic Lateral Sclerosis[NCT00355576] | Phase 2 | 86 participants (Actual) | Interventional | 2006-07-31 | Completed | ||
| Coenzyme Q10 in Huntington's Disease (HD)[NCT00608881] | Phase 3 | 609 participants (Actual) | Interventional | 2008-03-31 | Terminated (stopped due to Futility analysis failed to showed likelihoo of benefit of CoQ 2400 mg/day.) | ||
| Premanifest Huntington's Disease: Creatine Safety & Tolerability Extension Study[NCT01411150] | Phase 2 | 38 participants (Actual) | Interventional | 2009-05-31 | Completed | ||
| Creatine Safety, Tolerability, & Efficacy in Huntington's Disease (CREST-E)[NCT00712426] | Phase 3 | 553 participants (Actual) | Interventional | 2009-09-30 | Terminated (stopped due to Results of an interim analysis showed that it was unlikely that creatine was effective in slowing loss of function in early symptomatic Huntington's Disease.) | ||
| Premanifest Huntington's Disease Extension Study II: Creatine Safety & Tolerability[NCT01411163] | Phase 2 | 24 participants (Actual) | Interventional | 2010-04-30 | Completed | ||
| Creatine Safety and Tolerability in Premanifest HD: PRECREST[NCT00592995] | Phase 2 | 64 participants (Actual) | Interventional | 2007-12-31 | Completed | ||
| Creatine Safety & Tolerability in Huntington's Disease (CREST-X): A Single-Center, Open-Label, Long-Term Safety & Tolerability Extension Study of Creatine in Subjects With HD[NCT01412151] | Phase 2 | 10 participants (Actual) | Interventional | 2005-04-30 | Completed | ||
| Phase 3 Trial of Coenzyme Q10 in Mitochondrial Disease[NCT00432744] | Phase 3 | 24 participants (Actual) | Interventional | 2007-01-31 | Completed | ||
| An Investigation Examining the Evidence for Mitochondrial Dysfunction in the Pathophysiology and Treatment of Bipolar Disorder[NCT00327756] | Phase 2 | 0 participants (Actual) | Interventional | 2006-05-31 | Withdrawn | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The Unified Huntington's Disease Rating Scale (UHDRS) behavioral subscale assesses frequency and severity of psychiatric-related symptoms, including depressed mood, apathy, low self-esteem/guilt, suicidal thoughts, anxiety, irritable behavior, aggressive behavior, obsessional thinking, compulsive behavior, delusions, and hallucinations. A total score was calculated by summing up all the individual behavioral frequency items (range 0-56) with higher scores representing more severe behavioral impairment. (NCT00608881)
Timeframe: Baseline and Month 60
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| A - Coenzyme Q10 2400 mg/Day | 1.39 |
| B - Placebo | 1.43 |
The Unified Huntington's Disease Rating Scale (UHDRS) behavioral subscale assesses frequency and severity of psychiatric-related symptoms, including depressed mood, apathy, low self-esteem/guilt, suicidal thoughts, anxiety, irritable behavior, aggressive behavior, obsessional thinking, compulsive behavior, delusions, and hallucinations. The total score is the sum of the product of the individual behavioral frequency and severity items (range 0-176) with higher scores representing more severe behavioral impairment. (NCT00608881)
Timeframe: Baseline and Month 60
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| A - Coenzyme Q10 2400 mg/Day | 4.29 |
| B - Placebo | 5.06 |
"The functional assessment checklist includes 25 questions about common daily tasks. A score of 1 is given for each yes reply and a score of 0 is given for each no reply (scale range is 0-25). Higher scores indicate better functioning." (NCT00608881)
Timeframe: Baseline and Month 60
| Intervention | units on a scale (Mean) |
|---|---|
| A - Coenzyme Q10 2400 mg/Day | -7.93 |
| B - Placebo | -8.02 |
The independence scale assesses independence on a 0 to 100 scale with higher scores indicating better functioning. (NCT00608881)
Timeframe: Baseline and Month 60
| Intervention | units on a scale (Mean) |
|---|---|
| A - Coenzyme Q10 2400 mg/Day | -26.30 |
| B - Placebo | -24.86 |
Stroop Interference Test - color naming score is the total number of correct colors identified in 45 seconds and reflects processing speed. (NCT00608881)
Timeframe: Baseline and Month 60
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| A - Coenzyme Q10 2400 mg/Day | -14.21 |
| B - Placebo | -14.51 |
Stroop Interference Test - interference score is the total number of correct items identified in 45 seconds and reflects an executive measure of inhibitory ability. (NCT00608881)
Timeframe: Baseline and Month 60
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| A - Coenzyme Q10 2400 mg/Day | -7.57 |
| B - Placebo | -8.61 |
Stroop Interference Test - word reading score is the total number of correct words read in 45 seconds and reflects processing speed. (NCT00608881)
Timeframe: Baseline and Month 60
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| A - Coenzyme Q10 2400 mg/Day | -15.25 |
| B - Placebo | -19.13 |
The SDMT assesses attention, visuoperceptual processing, working memory, and cognitive/psychomotor speed. The score is the number of correctly paired abstract symbols and specific numbers in 90 seconds with higher scores indicating better cognitive functioning. (NCT00608881)
Timeframe: Baseline and Month 60
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| A - Coenzyme Q10 2400 mg/Day | -10.95 |
| B - Placebo | -11.36 |
TFC consists of five ordinally scaled items assessing a person's capacity with: (1) occupation; (2) financial affairs; (3) domestic responsibilities; (4) activities of daily living; and (5) independent living. Total score ranges from zero (worst) to 13 (best). (NCT00608881)
Timeframe: Baseline and Month 60
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| A - Coenzyme Q10 2400 mg/Day | -4.53 |
| B - Placebo | -4.76 |
The motor section of the Unified Huntington's Disease Rating Scale (UHDRS) assesses motor features of Huntington disease with standardized ratings of oculomotor function, dysarthria, chorea, dystonia, gait, and postural stability. The total motor score is the sum of all the individual motor ratings, with higher scores (124) indicating more severe motor impairment than lower scores. The score ranges from 0 to 124. (NCT00608881)
Timeframe: Baseline and Month 60
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| A - Coenzyme Q10 2400 mg/Day | 18.06 |
| B - Placebo | 19.18 |
The verbal fluency test is typically considered a measure of executive function. The score is the number of correct words produced across three 1-minute trials. (NCT00608881)
Timeframe: Baseline and Month 60
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| A - Coenzyme Q10 2400 mg/Day | -5.07 |
| B - Placebo | -4.47 |
The primary outcome variable at the start of the trial was the change in TFC score from baseline to Month 60. The Data and Safety Monitoring Board recommended to the trial leadership that they reconsider how they accommodate missing data from subjects who die in their primary analysis of the change in TFC score. Based on these recommendations, the trial leadership changed the primary analysis to that of a joint rank approach. TFC consists of five ordinally scaled items assessing a person's capacity with: (1) occupation; (2) financial affairs; (3) domestic responsibilities; (4) activities of daily living; and (5) independent living. Total score ranges from zero (worst) to 13 (best). (NCT00608881)
Timeframe: 5 years
| Intervention | rank (Mean) |
|---|---|
| A - Coenzyme Q10 2400 mg/Day | 303.3 |
| B - Placebo | 306.7 |
(NCT00608881)
Timeframe: 5 years
| Intervention | participants completing study on drug (Number) |
|---|---|
| A - Coenzyme Q10 2400 mg/Day | 98 |
| B - Placebo | 108 |
TFC consists of five ordinally scaled items assessing a person's capacity with: (1) occupation; (2) financial affairs; (3) domestic responsibilities; (4) activities of daily living; and (5) independent living. Total score ranges from zero (worst) to 13 (best). (NCT00608881)
Timeframe: 5 years
| Intervention | days to event (Median) |
|---|---|
| A - Coenzyme Q10 2400 mg/Day | 917 |
| B - Placebo | 911 |
TFC consists of five ordinally scaled items assessing a person's capacity with: (1) occupation; (2) financial affairs; (3) domestic responsibilities; (4) activities of daily living; and (5) independent living. Total score ranges from zero (worst) to 13 (best). (NCT00608881)
Timeframe: 5 years
| Intervention | days to event (Median) |
|---|---|
| A - Coenzyme Q10 2400 mg/Day | 553 |
| B - Placebo | 549 |
Proportion of subjects able to complete treatment (NCT01412151)
Timeframe: 306 Weeks
| Intervention | Participants (Number) |
|---|---|
| Creatine Monohydrate | 5 |
The McMaster Gross Motor Function is a validated scale ranging from 0 to 100 (the higher the better). Since there was the possibility of a subject becoming totally disabled our FDA peer reviewed design called for its use as follows: If the subject completed both periods, the score was calculated as the difference in scores between the end of Period 2 (at 12 months) minus that at the end of Period 1 (6 months). If a subject became totally disabled, this difference was considered as plus infinity if it occurred in period 1 (Penalizes period 1), and minus infinity if it occurred in Period 2 (Penalizes period 2). The two treatments were compared via the Wilcoxon test, and the effect size was estimated using Kendall's Tau-B. This is interpreted in a similar manner to correlation with positive values favoring COQenzyme10 and negative values favoring placebo. One of the links in this report is to the the GMFM scale and how it is scored. A link to the instrument is included. (NCT00432744)
Timeframe: Taken at 6 and 12 Months
| Intervention | units on a scale (Median) |
|---|---|
| Placebo First | -0.002 |
| CoenzymeQ10 Frist | -0.12 |
This is a multivariate analysis of the first two outcomes: Period 2 minus Period 1 GMFM88 and Peds Quality of Life, analyzed as follows: First, to be in the analysis, subjects must contribute at least one of these endpoints. Second, if the subject became totally disabled during period 1, the difference was defined as + infinity, (highest possible evidence favoring period 2), and if the subject became totally disabled in period 2, the subject was scored as - infinity (highest possible evidence favoring period 1). Period 2 minus period 1 differences were ranked form low to high with missing values scores at the mid-rank. The Hotelling T-square was computed on these ranks and the P-value was obtained from 100,000 rerandomizations as the fraction of rerandomizations with T-sq at least as large as that observed. (NCT00432744)
Timeframe: end of 12 month minus end of 6 month difference.
| Intervention | participants (Number) |
|---|---|
| Placebo First | 7 |
| CoenzymeQ10 Frist | 8 |
"The Pediatric Quality of Life Scale is a validated scale ranging from 0 to 100 (the higher the better). Since there was the possibility of a subject becoming totally disabled our FDA peer reviewed design called for its use as follows: If the subject completed both periods, the score was calculated as the difference in scores between the end of Period 2 (at 12 months) minus that at the end of Period 1 (6 months). If a subject became totally disabled, this difference was considered as plus infinity if it occurred in period 1 (Penalizes period 1), and minus infinity if it occurred in Period 2 (Penalizes period 2). The two treatments were compared via the Wilcoxon test, and the effect size was estimated using Kendall's Tau-B. This is interpreted in a similar manner to correlation with positive values favoring COQenzyme10 and negative values favoring placebo. Goggle pedsQL and Mapi to browse the copyrighted manual. A link to the instrument is included." (NCT00432744)
Timeframe: At 6 and 12 Months
| Intervention | units on a scale (Median) |
|---|---|
| Placebo First | -1.1 |
| CoenzymeQ10 Frist | -11.9 |
23 reviews available for creatine and Disease Models, Animal
| Article | Year |
|---|---|
Role of Creatine in the Heart: Health and Disease.
Topics: Animals; Anthracyclines; Cardiovascular Diseases; Creatine; Dietary Supplements; Disease Models, Ani | 2021 |
Intellectual Disability and Brain Creatine Deficit: Phenotyping of the Genetic Mouse Model for GAMT Deficiency.
Topics: Animals; Brain; Creatine; Disease Models, Animal; Guanidinoacetate N-Methyltransferase; Intellectual | 2021 |
Use of Vitamins and Dietary Supplements by Patients With Multiple Sclerosis: A Review.
Topics: Acetylcarnitine; Animals; Ascorbic Acid; Biotin; Caffeine; Creatine; Curcumin; Dietary Supplements; | 2018 |
Proton MRS in mild cognitive impairment.
Topics: Alzheimer Disease; Animals; Aspartic Acid; Biomarkers; Brain; Choline; Cognitive Dysfunction; Creati | 2013 |
Magnetic resonance spectroscopy biomarkers in term perinatal asphyxial encephalopathy: from neuropathological correlates to future clinical applications.
Topics: Animals; Animals, Newborn; Aspartic Acid; Asphyxia Neonatorum; Biomarkers; Choline; Creatine; Diseas | 2014 |
Neurochemistry of Hypomyelination Investigated with MR Spectroscopy.
Topics: Animals; Aspartic Acid; Brain Chemistry; Choline; Creatine; Demyelinating Diseases; Disease Models, | 2015 |
Augmentation of Creatine in the Heart.
Topics: Animals; Creatine; Creatine Kinase; Disease Models, Animal; Gene Expression; Heart; Heart Failure; H | 2016 |
The Effects of Creatine Supplementation and Physical Exercise on Traumatic Brain Injury.
Topics: Animals; Brain Injuries; Creatine; Disease Models, Animal; Exercise; Humans | 2016 |
Creatine for neuroprotection in neurodegenerative disease: end of story?
Topics: Animals; Creatine; Disease Models, Animal; Dose-Response Relationship, Drug; Humans; Neurodegenerati | 2016 |
Creatine synthesis and exchanges between brain cells: What can be learned from human creatine deficiencies and various experimental models?
Topics: Amidinotransferases; Amino Acid Metabolism, Inborn Errors; Animals; Blood-Brain Barrier; Brain Disea | 2016 |
Clinical use of creatine in neuromuscular and neurometabolic disorders.
Topics: Animals; Body Composition; Charcot-Marie-Tooth Disease; Creatine; Disease Models, Animal; Glycogen S | 2007 |
The neuroprotective role of creatine.
Topics: Acute Disease; Adenosine Triphosphate; Animals; Cell Death; Chronic Disease; Creatine; Disease Model | 2007 |
Creatine in mouse models of neurodegeneration and aging.
Topics: Aging; Animals; Creatine; Disease Models, Animal; Humans; Mice; Neurodegenerative Diseases; Rejuvena | 2011 |
Mitochondrial and metabolic-based protective strategies in Huntington's disease: the case of creatine and coenzyme Q.
Topics: Animals; Creatine; Disease Models, Animal; Humans; Huntington Disease; Metabolic Diseases; Mitochond | 2011 |
Inborn errors of creatine metabolism and epilepsy.
Topics: Amidinotransferases; Amino Acid Metabolism, Inborn Errors; Animals; Brain Diseases, Metabolic, Inbor | 2013 |
ALS, motor neuron disease, and related disorders: a personal approach to diagnosis and management.
Topics: Adolescent; Adult; Animals; Case Management; Combined Modality Therapy; Creatine; Diagnosis, Differe | 2002 |
Mitochondria, oxidative damage, and inflammation in Parkinson's disease.
Topics: Animals; Anti-Inflammatory Agents; Coenzymes; Creatine; Disease Models, Animal; Free Radicals; Human | 2003 |
Experimental therapeutics in Huntington's disease: are models useful for therapeutic trials?
Topics: Acetamides; Animals; Antioxidants; Creatine; Disease Models, Animal; Evaluation Studies as Topic; Hu | 2003 |
Targeting cellular energy production in neurological disorders.
Topics: Amyotrophic Lateral Sclerosis; Animals; Coenzymes; Creatine; Disease Models, Animal; Energy Metaboli | 2003 |
The role of creatine in the management of amyotrophic lateral sclerosis and other neurodegenerative disorders.
Topics: Amyotrophic Lateral Sclerosis; Animals; Creatine; Dietary Supplements; Disease Models, Animal; Human | 2004 |
Magnetic resonance spectroscopy in animal models of epilepsy.
Topics: Animals; Aspartic Acid; Brain; Carbon Isotopes; Choline; Creatine; Disease Models, Animal; Epilepsy; | 2007 |
[The effect of corticotherapy on respiratory muscles].
Topics: Adrenal Cortex Hormones; Aminoglycosides; Animals; Anti-Bacterial Agents; Chronic Disease; Clinical | 1998 |
Mizoribine and mycophenolate mofetil.
Topics: Animals; Arthritis; Carbon-Nitrogen Ligases; Cell Cycle; Cell Division; Clinical Trials as Topic; Cr | 1999 |
241 other studies available for creatine and Disease Models, Animal
| Article | Year |
|---|---|
Renal, hepatic and muscle effects of creatine supplementation in an older adults experimental model.
Topics: Aged; Animals; Creatine; Dietary Supplements; Disease Models, Animal; Humans; Kidney; Liver; Muscle, | 2022 |
Cyclocreatine Suppresses Creatine Metabolism and Impairs Prostate Cancer Progression.
Topics: Animals; Creatine; Creatinine; Disease Models, Animal; Humans; Intracellular Signaling Peptides and | 2022 |
Insights into the development of pentylenetetrazole-induced epileptic seizures from dynamic metabolomic changes.
Topics: Alanine; Animals; Anticonvulsants; Asparagine; Citrates; Creatine; Creatinine; Disease Models, Anima | 2022 |
Curcumin-driven reprogramming of the gut microbiota and metabolome ameliorates motor deficits and neuroinflammation in a mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Creatine; Curcumin; Disease Models, Animal; G | 2022 |
Spatio-temporal metabolic rewiring in the brain of TgF344-AD rat model of Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Brain; Choline; Creatine; Disease Models, Animal; Disease Progression; G | 2022 |
Mitochondrial creatine sensitivity is lost in the D2.
Topics: Animals; Creatine; Diaphragm; Disease Models, Animal; Mice; Mice, Inbred C57BL; Mice, Inbred mdx; Mu | 2023 |
Anti-inflammatory agent, OKN-007, reverses long-term neuroinflammatory responses in a rat encephalopathy model as assessed by multi-parametric MRI: implications for aging-associated neuroinflammation.
Topics: Animals; Anti-Inflammatory Agents; Aspartic Acid; Benzenesulfonates; Brain Diseases; Cerebral Cortex | 2019 |
Creatine transporter knockout mice (Slc6a8) show increases in serotonin-related proteins and are resilient to learned helplessness.
Topics: Animals; Anxiety; Behavior, Animal; Corpus Striatum; Creatine; Depression; Disease Models, Animal; E | 2020 |
Short-term creatine supplementation changes protein metabolism signaling in hindlimb suspension.
Topics: Animals; Creatine; Dietary Supplements; Disease Models, Animal; Hindlimb Suspension; Male; Muscle, S | 2019 |
Disruption of gut integrity and permeability contributes to enteritis in a fish-parasite model: a story told from serum metabolomics.
Topics: Animals; Cadherins; Claudin-3; Creatine; Dextrans; Disease Models, Animal; Electrophysiology; Enteri | 2019 |
Analysis of L-arginine:glycine amidinotransferase-, creatine- and homoarginine-dependent gene regulation in the murine heart.
Topics: Amidinotransferases; Animals; Arginine; Connective Tissue Growth Factor; Creatine; Desmocollins; Dis | 2020 |
Creatine and taurine mixtures alleviate depressive-like behaviour in Drosophila melanogaster and mice via regulating Akt and ERK/BDNF pathways.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Brain-Derived Neurotrophic Factor; Catecholamines; | 2020 |
Mechanism of Albuminuria Reduction by Chymase Inhibition in Diabetic Mice.
Topics: Albuminuria; Animals; Biomarkers; Blood Glucose; Body Weight; Chymases; Creatine; Diabetes Mellitus, | 2020 |
Cyclocreatine treatment ameliorates the cognitive, autistic and epileptic phenotype in a mouse model of Creatine Transporter Deficiency.
Topics: Animals; Autistic Disorder; Blood-Brain Barrier; Brain Diseases, Metabolic, Inborn; Cerebrovascular | 2020 |
Sex-Specific Effects of Chronic Creatine Supplementation on Hippocampal-Mediated Spatial Cognition in the 3xTg Mouse Model of Alzheimer's Disease.
Topics: Alzheimer Disease; Animals; Behavior, Animal; Creatine; Dietary Supplements; Disease Models, Animal; | 2020 |
Cardiac expression and location of hexokinase changes in a mouse model of pure creatine deficiency.
Topics: Adenosine Diphosphate; Adenylate Kinase; Amidinotransferases; Amino Acid Metabolism, Inborn Errors; | 2021 |
A new rat model of creatine transporter deficiency reveals behavioral disorder and altered brain metabolism.
Topics: Animals; Base Sequence; Behavior, Animal; Body Weight; Brain; Brain Diseases, Metabolic, Inborn; Cre | 2021 |
Resistance exercise training ameliorates chronic kidney disease outcomes in a 5/6 nephrectomy model.
Topics: Animals; Creatine; Disease Models, Animal; Male; Nephrectomy; Rats; Rats, Wistar; Renal Insufficienc | 2021 |
Long-Term Caloric Restriction Attenuates β-Amyloid Neuropathology and Is Accompanied by Autophagy in APPswe/PS1delta9 Mice.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animal Nutritional Physiological Phenomena; Animals; Aspar | 2021 |
5-aminolevulinic acid combined with sodium ferrous citrate ameliorated lupus nephritis in a mouse chronic graft-versus-host disease model.
Topics: Aminolevulinic Acid; Animals; B-Lymphocytes; Blood Urea Nitrogen; Body Weight; CD8-Positive T-Lympho | 2021 |
Early detection of Alzheimer's disease using creatine chemical exchange saturation transfer magnetic resonance imaging.
Topics: Alzheimer Disease; Amyloidosis; Animals; Biomarkers; Cerebral Cortex; Corpus Callosum; Creatine; Dis | 2021 |
Use of an animal model of disease for toxicology enables identification of a juvenile no observed adverse effect level for cyclocreatine in creatine transporter deficiency.
Topics: Animals; Antineoplastic Agents; Brain; Brain Diseases, Metabolic, Inborn; Creatine; Creatinine; Dise | 2021 |
The first knock-in rat model for glutaric aciduria type I allows further insights into pathophysiology in brain and periphery.
Topics: Amino Acid Metabolism, Inborn Errors; Animals; Arginine; Brain; Brain Diseases, Metabolic; Creatine; | 2021 |
Acetic acid treatment causes renal inflammation and chronic kidney disease in mice.
Topics: Acetic Acid; Animals; Creatine; Disease Models, Animal; Gene Expression; Interleukin-1beta; Kidney; | 2021 |
Creatine transporter deficiency impairs stress adaptation and brain energetics homeostasis.
Topics: Animals; Animals, Newborn; Brain; Brain Diseases, Metabolic, Inborn; Creatine; Disease Models, Anima | 2021 |
Creatine Supplementation Upregulates mTORC1 Signaling and Markers of Synaptic Plasticity in the Dentate Gyrus While Ameliorating LPS-Induced Cognitive Impairment in Female Rats.
Topics: Animal Nutritional Physiological Phenomena; Animals; Behavior, Animal; Cognitive Dysfunction; Creati | 2021 |
Roles of the Exogenous H2S-Mediated SR-A Signaling Pathway in Renal Ischemia/ Reperfusion Injury in Regulating Endoplasmic Reticulum Stress-Induced Autophagy in a Rat Model.
Topics: Animals; Autophagy; Creatine; Disease Models, Animal; Endoplasmic Reticulum Chaperone BiP; Endoplasm | 2017 |
NSCs promote hippocampal neurogenesis, metabolic changes and synaptogenesis in APP/PS1 transgenic mice.
Topics: Alzheimer Disease; Animals; Aspartic Acid; Cognition Disorders; Creatine; Disease Models, Animal; Gl | 2017 |
[Metabonomic analysis of the urine from rat model with abnormal sapra syndrome].
Topics: Amino Acids; Animals; Citric Acid; Creatine; Disease Models, Animal; Energy Metabolism; Glutamine; G | 2017 |
Optimized CEST cardiovascular magnetic resonance for assessment of metabolic activity in the heart.
Topics: Animals; Biomarkers; Case-Control Studies; Cicatrix; Contrast Media; Creatine; Creatine Kinase; Dise | 2017 |
Effects of creatine supplementation on nociception in young male and female mice.
Topics: Acid Sensing Ion Channels; Analgesics; Animals; Creatine; Disease Models, Animal; Female; Ganglia, S | 2018 |
Metabonomic profiling of chronic intermittent hypoxia in a mouse model.
Topics: Analysis of Variance; Animals; Creatine; Disease Models, Animal; Glucose Tolerance Test; Guanidinoac | 2018 |
Neuroprotective Effects of Creatine in the CMVMJD135 Mouse Model of Spinocerebellar Ataxia Type 3.
Topics: Animals; Ataxin-3; Brain; Calbindins; Creatine; Diet; Disease Models, Animal; Female; Follow-Up Stud | 2018 |
Creatine enhances the duration of sperm capacitation: a novel factor for improving in vitro fertilization with small numbers of sperm.
Topics: Animals; Blotting, Western; Creatine; Cumulus Cells; Disease Models, Animal; Female; Fertilization i | 2018 |
Myoprotective Potential of Creatine Is Greater than Whey Protein after Chemically-Induced Damage in Rat Skeletal Muscle.
Topics: Animals; Bupivacaine; Creatine; Cytoprotection; Dietary Supplements; Disease Models, Animal; Isometr | 2018 |
In Vivo Mapping and Quantification of Creatine Using Chemical Exchange Saturation Transfer Imaging in Rat Models of Epileptic Seizure.
Topics: Animals; Creatine; Disease Models, Animal; Image Processing, Computer-Assisted; Magnetic Resonance S | 2019 |
Subchronic administration of creatine produces antidepressant-like effect by modulating hippocampal signaling pathway mediated by FNDC5/BDNF/Akt in mice.
Topics: Animals; Antidepressive Agents; bcl-2-Associated X Protein; Brain-Derived Neurotrophic Factor; Creat | 2018 |
Metabolomic Analysis of Mouse Brain after a Transient Middle Cerebral Artery Occlusion by Mass Spectrometry Imaging.
Topics: Animals; Ceramides; Creatine; Disease Models, Animal; Infarction, Middle Cerebral Artery; Male; Meta | 2018 |
Biochemical Changes Indicate Developmental Stage in the Hippocampal Formation.
Topics: Age Factors; Animals; Brain; Creatine; Disease Models, Animal; Hippocampus; Male; Pilocarpine; Rats, | 2019 |
A Nervous System-Specific Model of Creatine Transporter Deficiency Recapitulates the Cognitive Endophenotype of the Disease: a Longitudinal Study.
Topics: Animals; Brain Diseases, Metabolic, Inborn; Cognitive Dysfunction; Creatine; Disease Models, Animal; | 2019 |
Sheathless CE-MS based metabolic profiling of kidney tissue section samples from a mouse model of Polycystic Kidney Disease.
Topics: Animals; Betaine; Carnitine; Creatine; Creatinine; Disease Models, Animal; Electrophoresis, Capillar | 2019 |
Renal effects of exendin-4 in an animal model of brain death.
Topics: Animals; Apoptosis; Brain Death; Creatine; Cytokines; Disease Models, Animal; Exenatide; Genes, bcl- | 2019 |
Creatine supplementation in Walker-256 tumor-bearing rats prevents skeletal muscle atrophy by attenuating systemic inflammation and protein degradation signaling.
Topics: Animals; Carcinoma 256, Walker; Creatine; Dietary Supplements; Disease Models, Animal; Inflammation; | 2020 |
Creatine supplementation impairs airway inflammation in an experimental model of asthma involving P2 × 7 receptor.
Topics: Animals; Asthma; Creatine; Dietary Supplements; Disease Models, Animal; Humans; Male; Mice; Mice, In | 2019 |
Obesity and Cage Environment Modulate Metabolism in the Zucker Rat: A Multiple Biological Matrix Approach to Characterizing Metabolic Phenomena.
Topics: Amino Acids, Branched-Chain; Animals; Choline; Creatine; Disease Models, Animal; Environment; Gastro | 2019 |
Longitudinal neurometabolic changes in the hippocampus of a rat model of chronic hepatic encephalopathy.
Topics: Ammonium Compounds; Animals; Ascorbic Acid; Astrocytes; Chronic Disease; Creatine; Disease Models, A | 2019 |
Effects of Creatine Supplementation on Muscle Fatigue in Rats Receiving Doxorubicin Treatment.
Topics: Animals; Creatine; Dietary Supplements; Disease Models, Animal; Doxorubicin; Hand Strength; Male; Mu | 2020 |
Creatine supplementation exacerbates ethanol-induced hepatic damage in mice.
Topics: Animals; Creatine; Dietary Supplements; Disease Models, Animal; Ethanol; Liver; Liver Diseases; Male | 2019 |
Creatine plus pyruvate supplementation prevents oxidative stress and phosphotransfer network disturbances in the brain of rats subjected to chemically-induced phenylketonuria.
Topics: Animals; Antioxidants; Blood-Brain Barrier; Brain; Creatine; Disease Models, Animal; Energy Metaboli | 2019 |
Female mice heterozygous for creatine transporter deficiency show moderate cognitive deficits.
Topics: Animals; Behavior, Animal; Brain; Brain Diseases, Metabolic, Inborn; Cognition Disorders; Creatine; | 2014 |
Neural metabolite changes in corpus striatum after rat multipotent mesenchymal stem cells transplanted in hemiparkinsonian rats by magnetic resonance spectroscopy.
Topics: Animals; Aspartic Acid; Cell Differentiation; Cell Survival; Choline; Corpus Striatum; Creatine; Dis | 2013 |
Unchanged mitochondrial organization and compartmentation of high-energy phosphates in creatine-deficient GAMT-/- mouse hearts.
Topics: Adenosine Diphosphate; Adenosine Triphosphatases; Adenosine Triphosphate; Animals; Creatine; Creatin | 2013 |
Differences in the hippocampal frequency of creatine inclusions between the acute and latent phases of pilocarpine model defined using synchrotron radiation-based FTIR microspectroscopy.
Topics: Animals; Behavior, Animal; Brain Mapping; Creatine; Disease Models, Animal; Epilepsy, Temporal Lobe; | 2013 |
Parkinson's disease: in vivo metabolic changes in the frontal and parietal cortices in 6-OHDA treated rats during different periods.
Topics: Animals; Aspartic Acid; Choline; Corpus Striatum; Creatine; Disease Models, Animal; Frontal Lobe; Fu | 2014 |
[Effects of adipose-derived stem cells on renal injury in burn mice with sepsis].
Topics: Adipose Tissue; Animals; Burns; Creatine; Cyclooxygenase 2; Disease Models, Animal; Interleukin-10; | 2013 |
Reduced levels of mitochondrial complex I subunit NDUFB8 and linked complex I + III oxidoreductase activity in the TgCRND8 mouse model of Alzheimer's disease.
Topics: Adenosine Triphosphate; Aging; Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Cardiolip | 2014 |
Human kallistatin administration reduces organ injury and improves survival in a mouse model of polymicrobial sepsis.
Topics: Animals; Apoptosis; Blood Urea Nitrogen; Caspase 3; Creatine; Disease Models, Animal; HMGB1 Protein; | 2014 |
Effects of l-arginine and creatine administration on spatial memory in rats subjected to a chronic variable stress model.
Topics: Animals; Arginine; Chronic Disease; Creatine; Disease Models, Animal; Male; Random Allocation; Rats; | 2014 |
[Effects of estrogen replacement therapy on cognitive function of ovariectomized rats].
Topics: Animals; Aspartic Acid; Cognition; Creatine; Disease Models, Animal; Estradiol; Estrogen Replacement | 2014 |
Effect of diet on brain metabolites and behavior in spontaneously hypertensive rats.
Topics: Animals; Aspartic Acid; Attention Deficit Disorder with Hyperactivity; Brain; Creatine; Dietary Fats | 2014 |
Stable isotope dilution microquantification of creatine metabolites in plasma, whole blood and dried blood spots for pharmacological studies in mouse models of creatine deficiency.
Topics: Amidinotransferases; Amino Acid Metabolism, Inborn Errors; Animals; Chromatography, Liquid; Creatine | 2014 |
Involvement of PKA, PKC, CAMK-II and MEK1/2 in the acute antidepressant-like effect of creatine in mice.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Calcium-Calmodulin-Dependent Protein Kinase Type 2 | 2014 |
Associations between in vivo neuroimaging and postmortem brain cytokine markers in a rodent model of Wernicke's encephalopathy.
Topics: Analysis of Variance; Animals; Aspartic Acid; Brain; Creatine; Cytokines; Disease Models, Animal; Li | 2014 |
Effects of ghrelin on sepsis-induced acute kidney injury: one step forward.
Topics: Acute Kidney Injury; Animals; Arterial Pressure; Blood Urea Nitrogen; Cecum; Creatine; Disease Model | 2015 |
MAGI-2 is critical for the formation and maintenance of the glomerular filtration barrier in mouse kidney.
Topics: Adaptor Proteins, Signal Transducing; Animals; Creatine; Disease Models, Animal; Female; Gene Expres | 2014 |
Pharmacokinetics of phosphocreatine and its active metabolite creatine in the mouse plasma and myocardium.
Topics: Adenosine Triphosphate; Animals; Chromatography, High Pressure Liquid; Creatine; Disease Models, Ani | 2014 |
Effect of bilirubin on triglyceride synthesis in streptozotocin-induced diabetic nephropathy.
Topics: Animals; Bilirubin; Cell Line, Tumor; Creatine; Diabetes Mellitus, Experimental; Diabetic Nephropath | 2014 |
Longitudinal cerebral metabolic changes in pig-tailed macaques infected with the neurovirulent virus SIVsmmFGb.
Topics: Animals; Aspartic Acid; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Choline; Corpus Stri | 2014 |
Long term creatine monohydrate supplementation, following neonatal hypoxic ischemic insult, improves neuromuscular coordination and spatial learning in male albino mouse.
Topics: Animals; Body Weight; Carotid Artery Diseases; Creatine; Disease Models, Animal; Hypoxia-Ischemia, B | 2015 |
Creatine monohydrate supplementation for 10 weeks mediates neuroprotection and improves learning/memory following neonatal hypoxia ischemia encephalopathy in female albino mice.
Topics: Analysis of Variance; Animals; Animals, Newborn; Creatine; Disease Models, Animal; Dose-Response Rel | 2015 |
High phosphorus level leads to aortic calcification via β-catenin in chronic kidney disease.
Topics: Actins; Animals; Aorta; beta Catenin; Blood Urea Nitrogen; Calcium; Cells, Cultured; Core Binding Fa | 2015 |
[Metabonomic analysis of the serum from rat model with abnormal balgam syndrome of Uyghur medicine].
Topics: Animals; Blood Glucose; Carboxylic Acids; Creatine; Disease Models, Animal; Lipoproteins, LDL; Male; | 2015 |
Early glial activation precedes neurodegeneration in the cerebral cortex after SIV infection: a 3D, multivoxel proton magnetic resonance spectroscopy study.
Topics: Animals; Aspartic Acid; Biomarkers; Central Nervous System Diseases; Cerebral Cortex; Choline; Creat | 2015 |
¹H- and ¹³C-NMR spectroscopy of Thy-1-APPSL mice brain extracts indicates metabolic changes in Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Aspartic Acid; Br | 2015 |
Cuprizone-induced demyelination and demyelination-associated inflammation result in different proton magnetic resonance metabolite spectra.
Topics: Animals; Aspartic Acid; Brain Chemistry; Choline; Creatine; Cuprizone; Demyelinating Diseases; Dipep | 2015 |
Early brain magnetic resonance imaging can predict short and long-term outcomes after organophosphate poisoning in a rat model.
Topics: Animals; Aspartic Acid; Atropine; Behavior, Animal; Brain; Brain Edema; Choline; Cholinesterase Reac | 2015 |
Protective effect of theophylline on renal functions in experimental pneumoperitoneum model.
Topics: Acute Kidney Injury; Animals; Biomarkers; Biopsy, Needle; Creatine; Cystatin C; Disease Models, Anim | 2015 |
Rhein prevents endotoxin-induced acute kidney injury by inhibiting NF-κB activities.
Topics: Acute Kidney Injury; Animals; Anthraquinones; Blood Urea Nitrogen; Cell Line; Creatine; Disease Mode | 2015 |
Neuroprotective efficacy of decompressive craniectomy after controlled cortical impact injury in rats: An MRI study.
Topics: Animals; Aspartic Acid; Brain; Brain Edema; Brain Injuries; Choline; Creatine; Decompressive Craniec | 2015 |
Metabolomics Identifies Biomarker Pattern for Early Diagnosis of Hepatocellular Carcinoma: from Diethylnitrosamine Treated Rats to Patients.
Topics: alpha-Fetoproteins; Animals; Betaine; Biomarkers, Tumor; Carcinoma, Hepatocellular; Cohort Studies; | 2015 |
Effect of creatine monohydrate supplementation on relative serum level of IL-6 and IL-18 following neonatal hypoxia ischemia in male albino mouse.
Topics: Animals; Animals, Newborn; Asphyxia Neonatorum; Biomarkers; Creatine; Dietary Supplements; Disease M | 2015 |
Creatine, Similar to Ketamine, Counteracts Depressive-Like Behavior Induced by Corticosterone via PI3K/Akt/mTOR Pathway.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Brain-Derived Neurotrophic Factor; Corticosterone; | 2016 |
Protective Effect of Creatine Elevation against Ischaemia Reperfusion Injury Is Retained in the Presence of Co-Morbidities and during Cardioplegia.
Topics: Age Factors; Animals; Comorbidity; Creatine; Disease Models, Animal; Female; Heart Arrest, Induced; | 2016 |
Effects of paternal and peripubertal stress on aggression, anxiety, and metabolic alterations in the lateral septum.
Topics: Age Factors; Aggression; Animals; Animals, Newborn; Anxiety Disorders; Aspartic Acid; Creatine; Dise | 2016 |
Maternal Creatine Supplementation during Pregnancy Prevents Long-Term Changes in Diaphragm Muscle Structure and Function after Birth Asphyxia.
Topics: Animals; Animals, Newborn; Asphyxia Neonatorum; Creatine; Diaphragm; Dietary Supplements; Disease Mo | 2016 |
Effects of anodal transcranial direct current stimulation (tDCS) on behavioral and spatial memory during the early stage of traumatic brain injury in the rats.
Topics: Analysis of Variance; Animals; Aspartic Acid; Brain Edema; Brain Injuries, Traumatic; Brain-Derived | 2016 |
[Continuous Veno-venous Hemofiltration in Goat Model with Crush Syndrome].
Topics: Acute Kidney Injury; Animals; Apoptosis; Creatine; Creatine Kinase; Crush Syndrome; Disease Models, | 2016 |
Paeoniflorin ameliorates acute necrotizing pancreatitis and pancreatitis‑induced acute renal injury.
Topics: Acute Kidney Injury; Amylases; Animals; Anti-Inflammatory Agents, Non-Steroidal; Biomarkers; Blood U | 2016 |
A mouse model for creatine transporter deficiency reveals early onset cognitive impairment and neuropathology associated with brain aging.
Topics: Aging; Animals; Brain; Brain Diseases, Metabolic, Inborn; Cognitive Dysfunction; Creatine; Disease M | 2016 |
Maternal creatine supplementation during pregnancy prevents acute and long-term deficits in skeletal muscle after birth asphyxia: a study of structure and function of hind limb muscle in the spiny mouse.
Topics: Animals; Animals, Newborn; Asphyxia Neonatorum; Creatine; Disease Models, Animal; Female; Hindlimb; | 2016 |
Medial Ganglionic Eminence Cells Freshly Obtained or Expanded as Neurospheres Show Distinct Cellular and Molecular Properties in Reducing Epileptic Seizures.
Topics: Animals; Cell Differentiation; Cells, Cultured; Creatine; Disease Models, Animal; Embryo, Mammalian; | 2017 |
Metabolic injury in a variable rat model of post-status epilepticus.
Topics: Animals; Aspartic Acid; Cluster Analysis; Creatine; Disease Models, Animal; Electroencephalography; | 2016 |
Pro- and anti-inflammatory cytokines release in mice injected with Crotalus durissus terrificus venom.
Topics: Animals; Creatine; Crotalid Venoms; Crotalus; Cytokines; Disease Models, Animal; Female; Interleukin | 2008 |
Hypothermia reduces cytotoxic edema and metabolic alterations during the acute phase of massive SAH: a diffusion-weighted imaging and spectroscopy study in rats.
Topics: Acute Disease; Animals; Aspartic Acid; Body Temperature; Brain; Brain Edema; Cerebral Cortex; Creati | 2008 |
Pre-existing renal disease promotes sepsis-induced acute kidney injury and worsens outcome.
Topics: Animals; Capillary Permeability; Creatine; Disease Models, Animal; Hemodynamics; Interleukin-10; Kid | 2008 |
A piglet model for detection of hypoxic-ischemic brain injury with magnetic resonance imaging.
Topics: Animals; Animals, Newborn; Aspartic Acid; Basal Ganglia; Brain; Brain Chemistry; Choline; Creatine; | 2008 |
Oral creatine supplementation attenuates L-DOPA-induced dyskinesia in 6-hydroxydopamine-lesioned rats.
Topics: Administration, Oral; Analysis of Variance; Animals; Creatine; Dietary Supplements; Disease Models, | 2009 |
Pulse push/pull hemodialysis in a canine renal failure model.
Topics: Animals; Creatine; Disease Models, Animal; Dogs; Equipment Design; Membranes, Artificial; Permeabili | 2008 |
Distinct MRI pattern in lesional and perilesional area after traumatic brain injury in rat--11 months follow-up.
Topics: Animals; Aspartic Acid; Brain; Brain Chemistry; Brain Injuries; Creatine; Diffusion Magnetic Resonan | 2009 |
Increased metabolite concentration in migraine rat model by proton MR spectroscopy in vivo and ex vivo.
Topics: Animals; Aspartic Acid; Cerebellum; Choline; Creatine; Disease Models, Animal; Magnetic Resonance Im | 2008 |
Neurochemical changes in a mouse model of Rett syndrome: changes over time and in response to perinatal choline nutritional supplementation.
Topics: Age Factors; Animals; Animals, Newborn; Aspartic Acid; Brain; Choline; Creatine; Dietary Supplements | 2009 |
Proton magnetic resonance spectroscopic findings of cerebral fat embolism induced by triolein emulsion in cats.
Topics: Animals; Aspartic Acid; Brain; Cats; Choline; Contrast Media; Creatine; Disease Models, Animal; Dise | 2008 |
Gray matter metabolism in acute and chronic hydrocephalus.
Topics: Analysis of Variance; Animals; Aspartic Acid; Brain; Brain Chemistry; Brain Mapping; Creatine; Disea | 2009 |
Neuronal activation in the CNS during different forms of acute renal failure in rats.
Topics: Acute Kidney Injury; Animals; Biogenic Amines; Body Weight; Brain; Creatine; Disease Models, Animal; | 2009 |
Combination therapy with coenzyme Q10 and creatine produces additive neuroprotective effects in models of Parkinson's and Huntington's diseases.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 8-Hydroxy-2'-Deoxyguanosine; alpha-Synuclein; Analysis | 2009 |
In vivo neuroprotection by a creatine-derived compound: phosphocreatine-Mg-complex acetate.
Topics: Animals; Brain Infarction; Brain Ischemia; Creatine; Cytoprotection; Disease Models, Animal; Infarct | 2009 |
In vivo proton magnetic resonance spectroscopy reveals region specific metabolic responses to SIV infection in the macaque brain.
Topics: Animals; Aspartic Acid; Brain; Brain Mapping; Choline; Creatine; Disease Models, Animal; Female; Ino | 2009 |
Exercise reduces effects of creatine on lung.
Topics: Animals; Asthma; Bronchoalveolar Lavage Fluid; Bronchoconstriction; Creatine; Disease Models, Animal | 2009 |
Temporal and regional changes after focal traumatic brain injury.
Topics: Animals; Aspartic Acid; Brain; Brain Edema; Brain Injuries; Brain Mapping; Cerebral Cortex; Choline; | 2010 |
Chronic creatine supplementation alters depression-like behavior in rodents in a sex-dependent manner.
Topics: Analysis of Variance; Animals; Antidepressive Agents; Body Temperature; Creatine; Depression; Diseas | 2010 |
Therapeutic benefits of human mesenchymal stem cells derived from bone marrow after global cerebral ischemia.
Topics: Analysis of Variance; Animals; Bone Marrow Cells; Brain Ischemia; Brain-Derived Neurotrophic Factor; | 2010 |
Magnetic resonance spectroscopy of regional brain metabolite markers in FALS mice and the effects of dietary creatine supplementation.
Topics: Amyotrophic Lateral Sclerosis; Animals; Aspartic Acid; Biomarkers; Brain; Creatine; Disease Models, | 2009 |
Neuronal and axonal degeneration in experimental spinal cord injury: in vivo proton magnetic resonance spectroscopy and histology.
Topics: Animals; Aspartic Acid; Choline; Creatine; Disease Models, Animal; Disease Progression; Gliosis; Imm | 2010 |
Retinal metabolic state of the proline-23-histidine rat model of retinitis pigmentosa.
Topics: Adenosine Triphosphate; Age Factors; Animals; Apoptosis; Ca(2+) Mg(2+)-ATPase; Coumaric Acids; Creat | 2010 |
Action of tacrolimus on Wistar rat kidneys implanted with Walker 256 carcinosarcoma.
Topics: Analysis of Variance; Animals; Blood Urea Nitrogen; Carcinoma 256, Walker; Creatine; Disease Models, | 2010 |
Characterization of cardiac remodeling in a large animal "one-kidney, one-clip" hypertensive model.
Topics: Animals; Blood Pressure; Creatine; Disease Models, Animal; Heart; Heart Atria; Hypertension; Kidney; | 2010 |
A new experimental model for acute hepatic failure in rats.
Topics: Ammonia; Animals; Bilirubin; Creatine; Disease Models, Animal; Hepatectomy; Hepatic Encephalopathy; | 2010 |
Desipramine attenuates forced swim test-induced behavioral and neurochemical alterations in mice: an in vivo(1)H-MRS study at 9.4T.
Topics: Animals; Behavior, Animal; Brain Chemistry; Choline; Creatine; Desipramine; Disease Models, Animal; | 2010 |
Association among amyloid plaque, lipid, and creatine in hippocampus of TgCRND8 mouse model for Alzheimer disease.
Topics: Alzheimer Disease; Amino Acid Substitution; Amyloid beta-Protein Precursor; Animals; Creatine; Disea | 2010 |
Reduction of hippocampal N-acetyl aspartate level in aged APP(Swe)/PS1(dE9) transgenic mice is associated with degeneration of CA3 pyramidal neurons.
Topics: Aging; Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Aspartic Acid; Benzothiazoles; CA | 2010 |
Creatine prevents the inhibition of energy metabolism and lipid peroxidation in rats subjected to GAA administration.
Topics: Animals; Brain Diseases, Metabolic; Creatine; Disease Models, Animal; Energy Metabolism; Glycine; Gu | 2010 |
Identification of the NC1 domain of {alpha}3 chain as critical for {alpha}3{alpha}4{alpha}5 type IV collagen network assembly.
Topics: Albumins; Amino Acid Sequence; Animals; Collagen; Collagen Type IV; Creatine; Disease Models, Animal | 2010 |
Effects of creatine and β-guanidinopropionic acid and alterations in creatine transporter and creatine kinases expression in acute seizure and chronic epilepsy models.
Topics: Acute Disease; Animals; CA1 Region, Hippocampal; Chronic Disease; Creatine; Creatine Kinase; Disease | 2010 |
Assessment of metabolic changes in the striatum of a MPTP-intoxicated canine model: in vivo ¹H-MRS study of an animal model for Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Aspartic Acid; Choline; Corpus Striatum; Crea | 2011 |
A metabonomic comparison of urinary changes in Zucker and GK rats.
Topics: Acids, Acyclic; Animals; Biomarkers; Creatine; Diabetes Mellitus, Type 2; Dimethylamines; Disease Mo | 2010 |
Creatine activates airway epithelium in asthma.
Topics: Animals; Asthma; Bronchoalveolar Lavage Fluid; Cell Proliferation; Creatine; Disease Models, Animal; | 2010 |
Creatine transporter (CrT; Slc6a8) knockout mice as a model of human CrT deficiency.
Topics: Animals; Brain Chemistry; Creatine; Disease Models, Animal; Female; Humans; Indoles; Learning Disabi | 2011 |
Dysregulated brain creatine kinase is associated with hearing impairment in mouse models of Huntington disease.
Topics: Adult; Animals; Audiometry, Pure-Tone; Blotting, Western; Case-Control Studies; Cochlea; Creatine; C | 2011 |
Effects of coenzyme Q and creatine supplementation on brain energy metabolism in rats exposed to chronic cerebral hypoperfusion.
Topics: Animals; Cerebral Cortex; Chronic Disease; Citrates; Creatine; Dietary Supplements; Disease Models, | 2011 |
A maternal diet supplemented with creatine from mid-pregnancy protects the newborn spiny mouse brain from birth hypoxia.
Topics: Animals; Animals, Newborn; Creatine; Dietary Supplements; Disease Models, Animal; Female; Fetal Hypo | 2011 |
Evaluation of phytoconstituents and anti-nephrotoxic and antioxidant activities of Monochoria vaginalis.
Topics: Acetaminophen; Animals; Antioxidants; Creatine; Disease Models, Animal; Ethanol; Kidney Diseases; Ma | 2011 |
Ozone therapy prevents renal inflammation and fibrosis in a rat model of acute pyelonephritis.
Topics: Acute Disease; Animals; Anti-Bacterial Agents; Aspartate Aminotransferases; Calcitonin; Ciprofloxaci | 2011 |
Tianeptine reverses stress-induced asymmetrical hippocampal volume and N-acetylaspartate loss in rats: an in vivo study.
Topics: Analysis of Variance; Animals; Antidepressive Agents, Tricyclic; Aspartic Acid; Choline; Chromatogra | 2011 |
Creatine reduces oxidative stress markers but does not protect against seizure susceptibility after severe traumatic brain injury.
Topics: Animals; Brain Injuries; Creatine; Dietary Supplements; Disease Models, Animal; Electroencephalograp | 2012 |
Supplementation of Nigella sativa fixed and essential oil mediates potassium bromate induced oxidative stress and multiple organ toxicity.
Topics: Animals; Biomarkers; Bromates; Creatine; Disease Models, Animal; Drug Evaluation, Preclinical; Heart | 2012 |
Learning and memory alterations are associated with hippocampal N-acetylaspartate in a rat model of depression as measured by 1H-MRS.
Topics: Animals; Aspartic Acid; Behavior, Animal; Citalopram; Creatine; Depression; Disease Models, Animal; | 2011 |
Tyrosine impairs enzymes of energy metabolism in cerebral cortex of rats.
Topics: Adenylate Kinase; Animals; Cerebral Cortex; Creatine; Disease Models, Animal; Energy Metabolism; Enz | 2012 |
Systematic evaluation of magnetic resonance imaging and spectroscopy techniques for imaging a transgenic model of Alzheimer's disease (AβPP/PS1).
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Biomarkers; Brain; Cell Proliferation; Choline; C | 2012 |
Changes in glucose metabolism and metabolites during the epileptogenic process in the lithium-pilocarpine model of epilepsy.
Topics: Animals; Aspartic Acid; Brain Mapping; Choline; Creatine; Disease Models, Animal; Epilepsy; Fluorode | 2012 |
Sex-specific antidepressant effects of dietary creatine with and without sub-acute fluoxetine in rats.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Brain; Creatine; Depression; Dietary Supplements; | 2012 |
Non-invasive in vivo detection of peripheral limb ischemia improvement in the rat after adipose tissue-derived stromal cell transplantation.
Topics: Actinin; Adipose Tissue; Animals; Blotting, Western; Cells, Cultured; Collagen Type III; Creatine; C | 2012 |
Antidepressant-like effect of creatine in mice involves dopaminergic activation.
Topics: Animals; Antidepressive Agents; Creatine; Depression; Disease Models, Animal; Dopamine; Dopamine Ago | 2012 |
Aristolochic acid-induced accumulation of methylglyoxal and Nε-(carboxymethyl)lysine: an important and novel pathway in the pathogenic mechanism for aristolochic acid nephropathy.
Topics: Animals; Aristolochic Acids; Creatine; Disease Models, Animal; Female; Kidney; Lysine; Mice; Mice, I | 2012 |
Age-related changes in brain metabolites and cognitive function in APP/PS1 transgenic mice.
Topics: Aging; Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Aspartic Acid; Biomarkers; Cholin | 2012 |
Moderate elevation of intracellular creatine by targeting the creatine transporter protects mice from acute myocardial infarction.
Topics: Animals; Cell Line; Creatine; Disease Models, Animal; Energy Metabolism; Glycogen; Heart Failure; Ma | 2012 |
Altered neurochemical profile in the McGill-R-Thy1-APP rat model of Alzheimer's disease: a longitudinal in vivo 1 H MRS study.
Topics: Age Factors; Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Aspartic Acid; Choline; Cre | 2012 |
MICEST: a potential tool for non-invasive detection of molecular changes in Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Aspartic Acid; Biomarkers; Brain Mapping | 2013 |
Cerebral blood flow and metabolic changes in hippocampal regions of a modified rat model with chronic cerebral hypoperfusion.
Topics: Animals; Aspartic Acid; Cerebrovascular Circulation; Creatine; Disease Models, Animal; Hippocampus; | 2013 |
Creatine pretreatment prevents birth asphyxia-induced injury of the newborn spiny mouse kidney.
Topics: Acute Kidney Injury; Animals; Asphyxia Neonatorum; Biomarkers; Creatine; Cytoprotection; Dietary Sup | 2013 |
Cordyceps sinensis protects against renal ischemia/reperfusion injury in rats.
Topics: Adenosine; Animals; Cellular Senescence; Chemokine CXCL12; Cordyceps; Creatine; Disease Models, Anim | 2013 |
The human OPA1delTTAG mutation induces premature age-related systemic neurodegeneration in mouse.
Topics: Acoustic Stimulation; Age Factors; Aging, Premature; Animals; Aspartic Acid; Chi-Square Distribution | 2012 |
Longitudinal monitoring of sex-related in vivo metabolic changes in the brain of Alzheimer's disease transgenic mouse using magnetic resonance spectroscopy.
Topics: Age Factors; Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Analysis of V | 2013 |
The activation of α1-adrenoceptors is implicated in the antidepressant-like effect of creatine in the tail suspension test.
Topics: Adrenergic Agents; alpha-Methyltyrosine; Analysis of Variance; Animals; Antidepressive Agents; Creat | 2013 |
Investigation of repeated vaccination as a possible cause of glomerular disease in mink.
Topics: Animals; Antibodies, Viral; Botulism; Complement System Proteins; Creatine; Disease Models, Animal; | 2002 |
Protective effects of oral creatine supplementation on spinal cord injury in rats.
Topics: Administration, Oral; Animals; Creatine; Dietary Supplements; Disease Models, Animal; Female; Glial | 2002 |
Additive neuroprotective effects of minocycline with creatine in a mouse model of ALS.
Topics: Amyotrophic Lateral Sclerosis; Animals; Anti-Bacterial Agents; Creatine; Disease Models, Animal; Dru | 2003 |
Long-term dietary L-arginine supplementation attenuates proteinuria and focal glomerulosclerosis in experimental chronic renal transplant failure.
Topics: Animals; Arginine; Blood Pressure; Creatine; Dietary Supplements; Disease Models, Animal; Glomerulos | 2003 |
Proton magnetic resonance imaging and spectroscopy identify metabolic changes in the striatum in the MPTP feline model of parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Aspartic Acid; Brain; Cats; Choline; Corpus S | 2003 |
Creatine protects against the convulsive behavior and lactate production elicited by the intrastriatal injection of methylmalonate.
Topics: Animals; Behavior, Animal; Corpus Striatum; Creatine; Disease Models, Animal; Dizocilpine Maleate; D | 2003 |
Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice.
Topics: Adenosine Triphosphate; Administration, Oral; Animals; Body Weight; Brain; Corpus Striatum; Creatine | 2003 |
Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice.
Topics: Adenosine Triphosphate; Administration, Oral; Animals; Body Weight; Brain; Corpus Striatum; Creatine | 2003 |
Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice.
Topics: Adenosine Triphosphate; Administration, Oral; Animals; Body Weight; Brain; Corpus Striatum; Creatine | 2003 |
Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice.
Topics: Adenosine Triphosphate; Administration, Oral; Animals; Body Weight; Brain; Corpus Striatum; Creatine | 2003 |
Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice.
Topics: Adenosine Triphosphate; Administration, Oral; Animals; Body Weight; Brain; Corpus Striatum; Creatine | 2003 |
Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice.
Topics: Adenosine Triphosphate; Administration, Oral; Animals; Body Weight; Brain; Corpus Striatum; Creatine | 2003 |
Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice.
Topics: Adenosine Triphosphate; Administration, Oral; Animals; Body Weight; Brain; Corpus Striatum; Creatine | 2003 |
Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice.
Topics: Adenosine Triphosphate; Administration, Oral; Animals; Body Weight; Brain; Corpus Striatum; Creatine | 2003 |
Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice.
Topics: Adenosine Triphosphate; Administration, Oral; Animals; Body Weight; Brain; Corpus Striatum; Creatine | 2003 |
Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice.
Topics: Adenosine Triphosphate; Administration, Oral; Animals; Body Weight; Brain; Corpus Striatum; Creatine | 2003 |
Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice.
Topics: Adenosine Triphosphate; Administration, Oral; Animals; Body Weight; Brain; Corpus Striatum; Creatine | 2003 |
Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice.
Topics: Adenosine Triphosphate; Administration, Oral; Animals; Body Weight; Brain; Corpus Striatum; Creatine | 2003 |
Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice.
Topics: Adenosine Triphosphate; Administration, Oral; Animals; Body Weight; Brain; Corpus Striatum; Creatine | 2003 |
Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice.
Topics: Adenosine Triphosphate; Administration, Oral; Animals; Body Weight; Brain; Corpus Striatum; Creatine | 2003 |
Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice.
Topics: Adenosine Triphosphate; Administration, Oral; Animals; Body Weight; Brain; Corpus Striatum; Creatine | 2003 |
Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice.
Topics: Adenosine Triphosphate; Administration, Oral; Animals; Body Weight; Brain; Corpus Striatum; Creatine | 2003 |
Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice.
Topics: Adenosine Triphosphate; Administration, Oral; Animals; Body Weight; Brain; Corpus Striatum; Creatine | 2003 |
Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice.
Topics: Adenosine Triphosphate; Administration, Oral; Animals; Body Weight; Brain; Corpus Striatum; Creatine | 2003 |
Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice.
Topics: Adenosine Triphosphate; Administration, Oral; Animals; Body Weight; Brain; Corpus Striatum; Creatine | 2003 |
Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice.
Topics: Adenosine Triphosphate; Administration, Oral; Animals; Body Weight; Brain; Corpus Striatum; Creatine | 2003 |
Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice.
Topics: Adenosine Triphosphate; Administration, Oral; Animals; Body Weight; Brain; Corpus Striatum; Creatine | 2003 |
Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice.
Topics: Adenosine Triphosphate; Administration, Oral; Animals; Body Weight; Brain; Corpus Striatum; Creatine | 2003 |
Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice.
Topics: Adenosine Triphosphate; Administration, Oral; Animals; Body Weight; Brain; Corpus Striatum; Creatine | 2003 |
Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice.
Topics: Adenosine Triphosphate; Administration, Oral; Animals; Body Weight; Brain; Corpus Striatum; Creatine | 2003 |
Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice.
Topics: Adenosine Triphosphate; Administration, Oral; Animals; Body Weight; Brain; Corpus Striatum; Creatine | 2003 |
Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice.
Topics: Adenosine Triphosphate; Administration, Oral; Animals; Body Weight; Brain; Corpus Striatum; Creatine | 2003 |
Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice.
Topics: Adenosine Triphosphate; Administration, Oral; Animals; Body Weight; Brain; Corpus Striatum; Creatine | 2003 |
Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice.
Topics: Adenosine Triphosphate; Administration, Oral; Animals; Body Weight; Brain; Corpus Striatum; Creatine | 2003 |
Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice.
Topics: Adenosine Triphosphate; Administration, Oral; Animals; Body Weight; Brain; Corpus Striatum; Creatine | 2003 |
Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice.
Topics: Adenosine Triphosphate; Administration, Oral; Animals; Body Weight; Brain; Corpus Striatum; Creatine | 2003 |
Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice.
Topics: Adenosine Triphosphate; Administration, Oral; Animals; Body Weight; Brain; Corpus Striatum; Creatine | 2003 |
Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice.
Topics: Adenosine Triphosphate; Administration, Oral; Animals; Body Weight; Brain; Corpus Striatum; Creatine | 2003 |
Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice.
Topics: Adenosine Triphosphate; Administration, Oral; Animals; Body Weight; Brain; Corpus Striatum; Creatine | 2003 |
Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice.
Topics: Adenosine Triphosphate; Administration, Oral; Animals; Body Weight; Brain; Corpus Striatum; Creatine | 2003 |
Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice.
Topics: Adenosine Triphosphate; Administration, Oral; Animals; Body Weight; Brain; Corpus Striatum; Creatine | 2003 |
Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice.
Topics: Adenosine Triphosphate; Administration, Oral; Animals; Body Weight; Brain; Corpus Striatum; Creatine | 2003 |
Creatine supplementation and riluzole treatment provide similar beneficial effects in copper, zinc superoxide dismutase (G93A) transgenic mice.
Topics: Age of Onset; Amyotrophic Lateral Sclerosis; Animals; Anterior Horn Cells; Cell Death; Cerebral Cort | 2003 |
Expression of glutamate transporter, GABRA6, serine proteinase inhibitor 2 and low levels of glutamate and GABA in the brain of knock-out mouse for Canavan disease.
Topics: Amino Acid Transport System X-AG; Analysis of Variance; Animals; Azo Compounds; Brain Chemistry; Can | 2003 |
Hippocampal N-acetyl aspartate levels do not mirror neuronal cell densities in creatine-supplemented epileptic rats.
Topics: Animals; Anticonvulsants; Aspartic Acid; Cell Count; Creatine; Diazepam; Disease Models, Animal; Epi | 2003 |
Additive neuroprotective effects of creatine and a cyclooxygenase 2 inhibitor against dopamine depletion in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease.
Topics: Animals; Creatine; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Disease | 2003 |
Dynamic magnetic resonance tomography and proton magnetic resonance spectroscopy of prostate cancers in rats treated by radiotherapy.
Topics: Animals; Antigens, CD34; Choline; Creatine; Disease Models, Animal; Immunohistochemistry; Magnetic R | 2004 |
Creatine protects the immature brain from hypoxic-ischemic injury.
Topics: Adenosine Triphosphate; Animals; Animals, Newborn; Brain; Creatine; Disease Models, Animal; Gestatio | 2004 |
Additive neuroprotective effects of creatine and cyclooxygenase 2 inhibitors in a transgenic mouse model of amyotrophic lateral sclerosis.
Topics: Amyotrophic Lateral Sclerosis; Animals; Creatine; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyc | 2004 |
Methamphetamine and AIDS: 1HMRS studies in a feline model of human disease.
Topics: Acquired Immunodeficiency Syndrome; Animals; Brain; Brain Chemistry; Cats; Choline; Creatine; Diseas | 2004 |
Development of canine nephrotic syndrome model.
Topics: Animals; Creatine; Disease Models, Animal; Dogs; Female; Glomerulonephritis; Immunohistochemistry; K | 2004 |
A prospective longitudinal in vivo 1H MR spectroscopy study of the SIV/macaque model of neuroAIDS.
Topics: Acute Disease; AIDS Dementia Complex; Animals; Aspartic Acid; Brain; Choline; Chronic Disease; Creat | 2004 |
Changes of renal lesion-related parameters in FGS/Nga and the parental mouse strains, CBA/N and RFM/Nga.
Topics: Animals; Blood Pressure; Blood Proteins; Blood Urea Nitrogen; Body Weight; Creatine; Disease Models, | 2004 |
In vitro 1H NMR spectroscopy shows an increase in N-acetylaspartylglutamate and glutamine content in the hippocampus of amygdaloid-kindled rats.
Topics: Amino Acids; Amygdala; Animals; Creatine; Dipeptides; Disease Models, Animal; Energy Metabolism; Epi | 2005 |
Brain creatine functions to attenuate acute stress responses through GABAnergic system in chicks.
Topics: Acute Disease; Adaptation, Physiological; Animals; Brain; Brain Chemistry; Chickens; Creatine; Disea | 2005 |
Biochemical and behavioural phenotyping of a mouse model for GAMT deficiency.
Topics: Animals; Behavior, Animal; Brain Chemistry; Creatine; Creatinine; Deficiency Diseases; Disease Model | 2005 |
Relationships between astrogliosis and 1H MR spectroscopic measures of brain choline/creatine and myo-inositol/creatine in a primate model.
Topics: Animals; Choline; Creatine; Disease Models, Animal; Glial Fibrillary Acidic Protein; Gliosis; Hydrog | 2005 |
Adoptive transfer of primed CD4+ T-lymphocytes induces pattern of chronic allograft nephropathy in a nude rat model.
Topics: Adoptive Transfer; Albumins; Animals; Antibodies; CD4-Positive T-Lymphocytes; Chronic Disease; Creat | 2005 |
Coregistration of quantitative proton magnetic resonance spectroscopic imaging with neuropathological and neurophysiological analyses defines the extent of neuronal impairments in murine human immunodeficiency virus type-1 encephalitis.
Topics: AIDS Dementia Complex; Animals; Aspartic Acid; Brain Mapping; Calcium-Binding Proteins; Capsid Prote | 2005 |
Effects of estradiol and dihydrotestosterone on osteoblast gene expression in osteopenic ovariectomized rats.
Topics: Animals; Bone Diseases, Metabolic; Calcium; Creatine; Dihydrotestosterone; Disease Models, Animal; D | 2005 |
Pulmonary intravascular volume can be used for dose calculation in isolated lung perfusion.
Topics: Albumins; Animals; Antineoplastic Agents; Blood Platelets; Chemotherapy, Cancer, Regional Perfusion; | 2005 |
Investigations into biochemical changes of genetic hypertensive rats using 1H nuclear magnetic resonance-based metabonomics.
Topics: Animals; Citric Acid; Creatine; Creatinine; Dimethylamines; Disease Models, Animal; Hypertension; Ke | 2005 |
Effects of creatine supplementation on body composition and renal function in rats.
Topics: Animals; Body Composition; Body Weight; Bone Density; Creatine; Dietary Supplements; Disease Models, | 2005 |
High resolution 1H NMR-based metabolomics indicates a neurotransmitter cycling deficit in cerebral tissue from a mouse model of Batten disease.
Topics: Aging; Animals; Aspartic Acid; Brain; Cerebellum; Cerebral Cortex; Creatine; Disease Models, Animal; | 2005 |
Dietary rescue of fumble--a Drosophila model for pantothenate-kinase-associated neurodegeneration.
Topics: Acetylcysteine; Adenosine Triphosphate; Animal Feed; Animals; Ascorbic Acid; Carnitine; Cloning, Mol | 2005 |
Creatine prevents behavioral alterations caused by methylmalonic acid administration into the hippocampus of rats in the open field task.
Topics: Animals; Avoidance Learning; Brain Diseases, Metabolic, Inborn; Creatine; Disease Models, Animal; En | 2006 |
Turbulence of glomerular hemodynamics involved in progressive glomerulosclerosis.
Topics: Albumins; Animals; Antibodies, Monoclonal; Blood Proteins; Blood Urea Nitrogen; Cholesterol; Creatin | 2006 |
Creatine supplementation increases soleus muscle creatine content and lowers the insulinogenic index in an animal model of inherited type 2 diabetes.
Topics: Adenosine Triphosphate; Animals; Blood Glucose; Body Weight; Creatine; Diabetes Mellitus, Type 2; Di | 2006 |
Improved reperfusion and neuroprotection by creatine in a mouse model of stroke.
Topics: Adenosine Triphosphate; Animals; Brain; Brain Ischemia; Cerebrovascular Circulation; Creatine; Disea | 2007 |
Altered renal sodium handling in spontaneously hypertensive rats (SHR) after hypertonic saline intracerebroventricular injection: role of renal nerves.
Topics: Animals; Blood Pressure; Creatine; Disease Models, Animal; Dose-Response Relationship, Drug; Hyperte | 2006 |
Acute and long-term effects of modified hemoglobin (HBOC-201) in a rat model of hypertension and chronic kidney disease.
Topics: Acute Disease; Animals; Blood Pressure; Blood Substitutes; Chronic Disease; Creatine; Disease Models | 2006 |
Intracerebroventricular administration of creatine protects against damage by global cerebral ischemia in rat.
Topics: Animals; Brain Ischemia; Cerebral Infarction; Creatine; Disease Models, Animal; Drug Administration | 2006 |
Regional metabolic status of the E-18 rat fetal brain following transient hypoxia/ischemia.
Topics: Adenosine Triphosphate; Animals; Brain; Creatine; Disease Models, Animal; Female; Fetal Hypoxia; Glu | 2006 |
Ouabain protects rat hearts against ischemia-reperfusion injury via pathway involving src kinase, mitoKATP, and ROS.
Topics: Adenosine Diphosphate; Animals; Cardiotonic Agents; Creatine; Disease Models, Animal; Heart Rate; Ma | 2007 |
In vivo effects of myocardial creatine depletion on left ventricular function, morphology, and energy metabolism--consequences in acute myocardial infarction.
Topics: Animals; Arrhythmias, Cardiac; Biomarkers; Catecholamines; Creatine; Disease Models, Animal; Electro | 2007 |
MRI and MRS alterations in the preclinical phase of murine prion disease: association with neuropathological and behavioural changes.
Topics: Animals; Aspartic Acid; Astrocytes; Body Water; Brain; Choline; Creatine; Diffusion; Disease Models, | 2007 |
Upregulation of the creatine synthetic pathway in skeletal muscles of mature mdx mice.
Topics: Age Factors; Amidinotransferases; Animals; Coloring Agents; Creatine; Disease Models, Animal; Energy | 2007 |
Time course of early metabolic changes following diffuse traumatic brain injury in rats as detected by (1)H NMR spectroscopy.
Topics: Amino Acids; Animals; Aspartic Acid; Brain; Brain Chemistry; Brain Injuries; Creatine; Diffuse Axona | 2007 |
Creatine decreases convulsions and neurochemical alterations induced by glutaric acid in rats.
Topics: Analysis of Variance; Animals; Anticonvulsants; Behavior, Animal; Brain Chemistry; Creatine; Disease | 2007 |
[Prevention of diltiazem in tacrolimus-induced nephrotoxicity: experiment with rats].
Topics: Animals; Creatine; Cyclosporine; Diltiazem; Disease Models, Animal; Dose-Response Relationship, Drug | 2007 |
Influence of N-acetylcysteine on renal toxicity of cadmium in rats.
Topics: Acetylcysteine; Animals; Cadmium Chloride; Catalase; Chemoprevention; Creatine; Disease Models, Anim | 2008 |
The effects of dantrolene on hypoxic-ischemic injury in the neonatal rat brain.
Topics: Animals; Animals, Newborn; Apoptosis; Aspartic Acid; Brain; Carotid Artery, Common; Creatine; Dantro | 2008 |
Metabonomic analysis identifies molecular changes associated with the pathophysiology and drug treatment of bipolar disorder.
Topics: Adult; Analysis of Variance; Animals; Antimanic Agents; Aspartic Acid; Bipolar Disorder; Case-Contro | 2009 |
Metabolic markers of neuronal injury correlate with SIV CNS disease severity and inoculum in the macaque model of neuroAIDS.
Topics: AIDS Dementia Complex; Analysis of Variance; Animals; Aspartic Acid; Choline; Creatine; Disease Mode | 2008 |
Magnetic resonance imaging and spectroscopy in a mouse model of schizophrenia.
Topics: Animals; Aspartic Acid; Brain; Choline; Creatine; Disease Models, Animal; Image Interpretation, Comp | 2008 |
[Estimation of postmortem interval with multivoxel-voxel proton 1H-MR spectroscopy].
Topics: Animals; Aspartic Acid; Biomarkers; Brain; Choline; Creatine; Disease Models, Animal; Embolism, Air; | 2007 |
Six-day kidney preservation in a canine model. Influence of a one-to-four-hour ex vivo perfusion interval.
Topics: Animals; Creatine; Disease Models, Animal; Dogs; Female; Kidney Transplantation; Male; Organ Preserv | 1983 |
Decreased energy reserve in an animal model of dilated cardiomyopathy. Relationship to contractile performance.
Topics: Adenosine Triphosphate; Animals; Cardiomyopathy, Dilated; Creatine; Creatine Kinase; Disease Models, | 1996 |
Neuroprotective effects of creatine and cyclocreatine in animal models of Huntington's disease.
Topics: Adenosine Triphosphate; Animals; Antihypertensive Agents; Antineoplastic Agents; Creatine; Creatinin | 1998 |
31P-NMR analysis of congestive heart failure in the SHHF/Mcc-facp rat heart.
Topics: Adenine Nucleotides; Adenosine Triphosphate; Animals; Creatine; Disease Models, Animal; Energy Metab | 1998 |
High-field proton magnetic resonance spectroscopy of a swine model for axonal injury.
Topics: Animals; Aspartic Acid; Axons; Brain; Brain Injuries; Creatine; Disease Models, Animal; Female; Magn | 1998 |
Changes in brain organic osmolytes in experimental cerebral ischemia.
Topics: Alanine; Amino Acids; Animals; Aspartic Acid; Brain Chemistry; Brain Ischemia; Creatine; Disease Mod | 1998 |
Neuronal pathology in the wobbler mouse brain revealed by in vivo proton magnetic resonance spectroscopy and immunocytochemistry.
Topics: Amyotrophic Lateral Sclerosis; Animals; Aspartic Acid; Axons; Caudate Nucleus; Creatine; Disease Mod | 1998 |
Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis.
Topics: Alanine; Amyotrophic Lateral Sclerosis; Animals; Creatine; Disease Models, Animal; Glycine; Humans; | 1999 |
Proton MRS of oral creatine supplementation in rats. Cerebral metabolite concentrations and ischemic challenge.
Topics: Administration, Oral; Anaerobiosis; Animals; Brain; Creatine; Dietary Supplements; Disease Models, A | 1999 |
Downregulation of the Na(+)-creatine cotransporter in failing human myocardium and in experimental heart failure.
Topics: Animals; Cardiomyopathy, Dilated; Carrier Proteins; Case-Control Studies; Creatine; Disease Models, | 1999 |
Postictal in situ MRS brain lactate in the rat kindling model.
Topics: Animals; Aspartic Acid; Brain Mapping; Creatine; Disease Models, Animal; Electroencephalography; Epi | 1999 |
Brain myo-inositol level is elevated in Ts65Dn mouse and reduced after lithium treatment.
Topics: Animals; Aspartic Acid; Brain; Choline; Creatine; Disease Models, Animal; Down Syndrome; Female; Ino | 2000 |
Win, place, show: creatine consumption and the price of winning.
Topics: Adolescent; Animals; Competitive Behavior; Creatine; Disease Models, Animal; Doping in Sports; Healt | 2001 |
In vitro 1H and 31P NMR spectroscopic evidence of multiple aberrant biochemical pathways in murine trisomy 16 brain development.
Topics: Alanine; Animals; Aspartic Acid; Biomarkers; Brain Chemistry; Choline; Creatine; Disease Models, Ani | 2000 |
Attenuating effect of a semipurified alcohol extract of soy protein on glomerular injury in spontaneous hypercholesterolemic male Imai rats.
Topics: Animals; Blood Pressure; Blood Urea Nitrogen; Body Weight; Caseins; Creatine; Dietary Proteins; Dise | 2001 |
Increases in cortical glutamate concentrations in transgenic amyotrophic lateral sclerosis mice are attenuated by creatine supplementation.
Topics: Amino Acid Transport System X-AG; Animals; ATP-Binding Cassette Transporters; Biological Transport; | 2001 |
Genetically modified bone marrow continuously supplies anti-inflammatory cells and suppresses renal injury in mouse Goodpasture syndrome.
Topics: Animals; Anti-Glomerular Basement Membrane Disease; Anti-Inflammatory Agents; Bone Marrow Cells; Bon | 2001 |
Oral administration of creatine monohydrate retards progression of motor neuron disease in the wobbler mouse.
Topics: Administration, Oral; Animals; Cell Count; Creatine; Disease Models, Animal; Disease Progression; Fo | 2000 |
Response of mitochondrial function to hypothyroidism in normal and regenerated rat skeletal muscle.
Topics: Animals; Cell Respiration; Citrate (si)-Synthase; Creatine; Creatine Kinase; Disease Models, Animal; | 2001 |
Inhibition of polyglutamine aggregation in R6/2 HD brain slices-complex dose-response profiles.
Topics: Animals; Benzoates; Biphenyl Compounds; Cells, Cultured; Coloring Agents; Congo Red; Creatine; Cyste | 2001 |
[Establishment of model of aristolochic acid-induced chronic renal interstitial fibrosis in rats].
Topics: Animals; Aristolochic Acids; Blood Urea Nitrogen; Body Weight; Carcinogens; Chronic Disease; Creatin | 2001 |
Effect of creatine monohydrate on cardiac function in a rat model of endotoxemia.
Topics: Adenosine Triphosphate; Animals; Cardiomyopathies; Creatine; Disease Models, Animal; Endotoxemia; In | 2002 |
Effects of glucose, insulin and potassium infusion on tissue metabolic changes within first hour of myocardial infarction in the baboon.
Topics: Adenosine Triphosphate; Animals; Coronary Vessels; Creatine; Disease Models, Animal; Dogs; Female; G | 1975 |
Effect on myocardial metabolic pattern of local complete and incomplete ischemia.
Topics: Adenosine Monophosphate; Animals; Coronary Disease; Creatine; Disease Models, Animal; Dogs; Glycogen | 1975 |
Effects of a new immunosuppressive agent, FK506, in rats with active Heymann nephritis.
Topics: Animals; Antibodies; Creatine; Disease Models, Animal; Female; Glomerulonephritis; Immunosuppressive | 1992 |
Pentoxifylline treatment of sepsis in conscious Yucatan minipigs.
Topics: Animals; Creatine; Disease Models, Animal; Escherichia coli; Hemodynamics; Oxygen; Pentoxifylline; S | 1992 |
Reduced intestinal permeability measured by differently sized polyethylene glycols in acute uremic rats.
Topics: Acute Kidney Injury; Animals; Cell Membrane Permeability; Computer Simulation; Creatine; Disease Mod | 1992 |
Amelioration of glomerular injury in doxorubicin hydrochloride nephrosis by dimethylthiourea.
Topics: Acetylglucosaminidase; Albuminuria; Animals; Benzoates; Benzoic Acid; Creatine; Dimethyl Sulfoxide; | 1991 |
[Abnormalities in mitochondrial creatine kinase activity in cardiomyopathic hamsters].
Topics: Adenosine Triphosphate; Animals; Cardiomyopathies; Creatine; Creatine Kinase; Cricetinae; Disease Mo | 1991 |
Chronic ciclosporin nephrotoxicity: a rabbit model.
Topics: Animals; Chronic Disease; Creatine; Cyclosporins; Disease Models, Animal; Injections, Intravenous; K | 1991 |
Role of the terminal complement pathway in accelerated autologous anti-glomerular basement membrane nephritis.
Topics: Animals; Basement Membrane; Complement Activation; Complement C6; Complement Pathway, Classical; Cre | 1990 |
Prevention of 11-deoxycorticosterone-salt-induced glomerular hypertrophy and glomerulosclerosis by dietary phosphate binder.
Topics: Aluminum Hydroxide; Animals; Antacids; Blood Pressure; Calcium; Creatine; Desoxycorticosterone; Dise | 1990 |
Adaptive decreases in amino acids (taurine in particular), creatine, and electrolytes prevent cerebral edema in chronically hyponatremic mice: rapid correction (experimental model of central pontine myelinolysis) causes dehydration and shrinkage of brain.
Topics: Acclimatization; Adenine Nucleotides; Amino Acids; Animals; Brain; Brain Edema; Creatine; Demyelinat | 1987 |
Limited-protein diet: a means of delaying the progression of chronic renal disease?
Topics: Adult; Animals; Chronic Disease; Creatine; Dietary Proteins; Disease Models, Animal; Glomerular Filt | 1985 |
Congestive heart failure following chronic tachycardia.
Topics: Adenosine Triphosphate; Animals; Blood Pressure; Cardiac Output; Chronic Disease; Creatine; Disease | 1971 |
Reduced renal arginine-glycine transamidinase activity in myotonic goats and in patients with myotonic muscular dystrophy.
Topics: Acetates; Adult; Aged; Animals; Arginine; Autopsy; Biopsy; Creatine; Disease Models, Animal; Glycine | 1969 |
[Effect of thyroxine on the course of acute renal failure. II. Effect of L-thyroxine administration on plasma level and kidney excretion of various substances in rabbits presenting acute kidney failure (studies using the so-called sublimate nephrosis mode
Topics: Acute Kidney Injury; Animals; Blood Glucose; Blood Proteins; Calcium; Chlorides; Cholesterol; Creati | 1971 |